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ABSTRACT 
The Effects of Transcutaneous Electrical Neurostimulation on Analgesia and Peripheral 
Perfusion 
 
Leah Schafer 
 
 Peripheral arterial occlusive disease (PAOD) affects 8 to 12 million Americans 
over the age of 50. As the disease progresses, arterial occlusions arising from 
atherosclerotic lesions inhibit normal metabolic vasodilation in the peripheries, resulting 
in limb ischemia and claudication. Pharmacological and surgical treatments currently 
used to treat both the hemodynamic and pain symptoms associated with PAOD can 
involve adverse and potentially life-threatening side effects. Thus, there is a need for 
additional innovative therapies for PAOD. 
 Neurostimulation has a known analgesic effect on both acute and chronic pain. 
Although the exact mechanisms remain under investigation, local vascular tone may be 
modulated by neurostimulation in addition to pain modulation. The Gate Control Theory 
proposes that electrical activation of mechanoreceptive afferent somatosensory nerves, 
specifically Aβ fibers, inhibits pain signaling to the brain by activating an inhibitory 
interneuron in the dorsal horn of the spinal cord which dampens signaling from afferent, 
C type peripheral nociceptor nerves. Interestingly, Aβ fiber activation may also inhibit 
norepinephrine release from sympathetic nerve terminals on efferent neurons by 
activating α-2 adrenergic receptors along the same dermatome, resulting in localized 
vasodilation in both limbs. Ultimately, electrical stimulation may decrease mean blood 
pressure and increase local blood flow. 
 The focus of this study was to optimize protocols and perform a small scale 
clinical study to investigate hemodynamic and analgesic responses to neurostimulation 
during acute ischemia. We hypothesized that ganglial transcutaneous electrical 
neurostimulation (TENS) and interferential current (IFC) treatments would decrease pain 
perception and vascular resistance in the periphery in young, healthy subjects. We further 
hypothesized that IFC may have a greater hyperemic and analgesic effect on acute 
ischemia than TENS as its current waveform may be more efficient at overcoming skin 
impedance. Interestingly, we found trends suggesting that TENS and IFC may increase 
vascular resistance (VR) and have no noticeable analgesic effect, though TENS may have 
a slightly lower increase in VR associated with an increase in pain. Further work 
characterizing the hemodynamic effects of different stimulus waveforms is needed to 
inform future research into possible neuromodulation therapies for ischemic disease.  
 
Keywords: Neurostimulation, ischemia, blood flow, hyperemia, vascular resistance, 
analgesia, peripheral artery occlusive disease 
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CHAPTER 1: INTRODUCTION 
 
1.1 PERIPHERAL ARTERY OCCLUSIVE DISEASE 
1.1.1 Prevalence and Etiology 
Peripheral arterial occlusive disease (PAOD) affects 10% of the American 
population, rising to 20% in persons over 70 years of age [1]. PAOD is more prevalent in 
men than in women, though non-fatal events are more frequent in women with PAOD 
than men [2]. Risk factors associated with PAOD also include diabetes, smoking, 
hypertension, and dyslipidemia [3], Figure 1.1. 
 
Figure 1.1: Risk Factors for PAOD. Gender, age, smoking, and diabetes effect the risk 
of developing PAOD [3]. Males have 10-20% greater risk than females. Increased age 
raises risk by 20-30% for each 10 year age bracket. Diabetes and smoking increase risk 
by 30-40%, while hypertension and dyslipidemia increase risk by 10-20%. 
 
PAOD is caused by atherosclerosis that leads to arterial stenosis in peripheral 
conduit arteries, Figure 1.2. Although resting blood flow in PAOD patients is similar to 
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that in a healthy person, arterial occlusions inhibit metabolic vasodilation in the 
peripheries, resulting in limb ischemia [4]. Once metabolic demands rise above tissue 
perfusion levels, muscle fatigue and acute ischemic pain result. The pain, also known as 
intermittent claudication (IC), and fatigue often subside after the cessation of muscle 
contraction and a return to resting metabolic demand. Although symptomatic stabilization 
may occur due to the development of collaterals, pain and fatigue can become chronic as 
arterial stenosis progresses [3]. 
 
 
Figure 1.2: Atherosclerotic Arterial Stenosis: The narrowing and hardening of 
peripheral arteries in PAOD causes decreased blood flow and vascular tone [5]. 
 
1.1.2 Diagnosis 
When claudication and fatigue symptoms occur, several tests are used to screen 
for PAOD. For artery disease in the legs, the most widely used test is the ankle-brachial 
systolic pressure index (ABI) which compares ankle blood pressure to arm pressure at 
rest. A resting ABI of ≤0.90 used as a hemodynamic definition of leg PAOD [6]. A 
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similar comparative blood pressure reading is used for PAOD screening in the arms, 
where a reduced blood pressure in one arm as compared to the other, as well as reduced 
pressure distal to the suspected blockage, is indicative of peripheral arterial stenosis. 
Diagnosing PAOD in asymptomatic patients requires advance screening. For this 
reason, coronary artery disease (CAD) can be indicative of PAOD in asymptomatic 
patients as PAOD and CAD are both manifestations of atherosclerosis. In the primary 
care setting, approximately half of patients diagnosed with PAOD also have CAD, and 
PAOD patients are at a higher risk for heart attacks and strokes [3]. Other hemodynamic 
imaging studies used to diagnose or characterize PAOD include Doppler ultrasound, 
magnetic resonance angiogram (MRA), and x-ray arteriogram. 
1.1.3 Current Treatment Options 
 Following diagnosis, current treatment options for PAOD include lifestyle 
changes, pharmacologic interventions, and/or surgery. Diet modification is directed 
toward lowering low density lipoprotein (LDL) consumption, as LDL cholesterol plays a 
major role in endothelial activation associated with atherosclerotic plaque formation [7]. 
Increasing exercise and smoking cessation are also important lifestyle changes known to 
decrease LDL concentration and improve overall cardiovascular health [8]. However, diet 
and exercise alone are often not sufficient to achieve recommended lipid levels; 
therefore, pharmacological treatments are often necessary.  
 Statins are prescribed to lower LDL cholesterol levels in PAOD patients and are 
associated with a 20% reduction in major adverse cardiovascular events such as 
myocardial infarction and stroke [9, 10]. Furthermore, the antiinflammatory, 
antiproliferative, and antithrombogenic properties of statins improve claudication and 
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atherosclerosis associated with PAOD [11]. Antihypertensive drugs such as diuretics, β-
adrenergic inhibitors (e.g. β-blockers), angiotensin-converting-enzyme (ACE) 
inhibitors/angiotensin receptor blockers, and calcium channel blockers are also 
commonly prescribed to reduce blood pressure (BP), which in turn slows the progression 
of atherosclerosis by reducing shear and oxidative stress in the blood vessel lumens. 
Thiazide diuretics are safe and effective for reducing BP in the general patient 
population, while ACE inhibitors are often used in patients with diabetic renal disease or 
congestive heart failure [12]. Calcium channel blockers are used in cases in which 
hypertension is more difficult to control, while adrenergic inhibitors are selectively used 
for cardioprotection in PAOD patients who also have concomitant coronary disease [3].  
 If drug therapies are insufficient, surgical intervention is also used to improve 
blood flow in PAOD patients. Percutaneous transluminal angioplasty (PTA) is a 
minimally invasive procedure used to compress atherosclerotic plaque inside the arterial 
wall, Figure 1.3. Long-term success rates for aortoiliac and femoropopliteal PTA are 
between 50-70% after 5 years [13]. However, hyperplasic restenosis due to a combination 
of localized inflammation, atherosclerosis, thrombosis, scar tissue formation, and 
proliferation [14, 15] occurs in up to 25–30% of PAOD patients and is a major problem 
limiting its long-term efficiency [11, 16]. Thus, angioplasty is often followed by stenting 
to preserve the structure of the vessel wall and reduce restenosis.  
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Figure 1.3: Percutaneous Angioplasty and Stenting. A. Intravascular deflated balloon 
catheter guidewire inserted into stenosed region. B. Non-stented balloon inflated; plaque 
compressed against arterial wall. C. Stented balloon inflated; plaque compressed and 
stent expanded. D. Stent preserves vessel shape and delays restenosis [17]. 
 
 Other intervention options for PAOD include atherectomy and bypass grafting. 
Rather than being compressed, plaque is removed by cutting, pulverizing, and shaving 
via a catheterized endarterectomy device. Although initial success is greater than PTA, 
restenosis and patency constraints occur in almost half of the patients at 12 months post-
atherectomy [18]. Arterial bypass grafting is a more invasive surgical intervention used 
as a last line of treatment for cases in which pharmacological or percutaneous 
interventions are not effective. This procedure involves redirecting blood flow around the 
stenosed section by attaching a healthy autologous or synthetic blood vessel at either end 
A B 
C D 
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of the blockage, Figure 1.4. However, over the past 20 years, the use of bypass surgery 
to treat PAOD has decreased by 42% in clinical settings [19]. 
 
Figure 1.4: Arterial Bypass Graft. Blood flow is redirected around the stenosed region 
by grafting a new vessel around the blockage [20]. 
 
 Cell-based therapies for PAOD are currently under investigation. An ongoing 
Stage 3 trial is investigating the safety and efficacy of autologous bone marrow aspirate 
concentrate (BMAC) for treating critical limb ischemia due to peripheral arterial disease 
[21]. It is postulated that intramuscular injections of BMAC into ischemic tissues will 
result in improved angiogenesis and blood flow. If successful, this treatment could 
improve blood flow and reduce ischemic pain.  
 Although treatment options do exist for PAOD and its symptoms, long-term 
efficacy is limited. Lifestyle changes may slow the progression of the disease, but may 
not be sufficient for disease management. Pharmacological and surgical complications 
are also prevalent. Statins impair memory, damage the liver, and raise blood sugar [22], 
while diuretics and beta-blockers may also cause insulin resistance [23]. Angioplasty and 
stenting have high restenosis rates and increase the thrombogenicity of the vessel wall, 
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while arterial grafts are very invasive and expensive and have a higher risk of major 
adverse cardiac events [24]. To more safely and effectively address PAOD and its 
symptoms, additional approaches are needed. Electrical stimulation is one such 
alternative to drug treatments for painful conditions and possibly ischemia. 
 
1.2 NEUROSTIMULATION 
1.2.1 Modalities and Functions 
 Several modalities of neurostimulation exist, including transcutaneous stimulation 
such as TENS and interferential current (IFC) as well as implanted technologies such as 
spinal cord stimulation (SCS) and deep brain stimulation. Implanted devices tend to be 
more effective at alleviating pain but carry a risk of device failure or surgical 
complication and are therefore reserved for more severe cases, while transcutaneous 
modalities have been proven to be safe and effective for the general patient population 
with more moderate pain and are available both clinically and commercially [25].  
 Both implanted and transcutaneous forms of neurostimulation have a known 
analgesic effect on patients suffering from acute [26, 27, 28] and chronic [29, 30, 31] 
pain, and on healthy subjects in whom acute pain has been induced experimentally [32, 
33, 34, 35]. Although clinical and experimental pain are not directly comparable, 
experimental pain is used to investigate pain pathophysiology and to evaluate analgesic 
effects under controlled conditions [36]. The onset and duration of analgesia may vary 
considerably between patients [37], and the same protocol may have different degrees of 
antinociception in acute experimental pain compared with chronic clinical pain [38]. 
Neurostimulation may also have a hyperemic effect [32, 39]. While the exact molecular 
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pathways for how neurostimulation achieves these effects remain under investigation, 
there is likely more than one mechanism of action.  
1.2.2 Mechanisms of Action  
1.2.2.1 Modulating Pain: Gate Control Theory and Endogenous Signaling 
 The most prevalent model for electrically-induced analgesia is the gate control 
theory (GCT). The GCT postulates that analgesia is achieved by electrical activation of 
afferent Aβ (large, cutaneous, myelinated) fibers which synapse onto ascending neurons 
in the central nervous system (CNS) on the same level as afferent C (small, cutaneous, 
unmyelinated) nociceptive fibers, Figure 1.5. Nociceptive signals traveling through C 
fibers from peripheral nociceptors activate second-order neurons in the substantia 
gelatinosa on dorsal horns along the spinothalamic tract (STT). STT neurons are 
responsible for carrying the signal to the thalamus for pain cognition.  
Neuropeptide substance P is involved with modulating ascending nociceptive 
information in the STT, as is nitric oxide (NO). NO activates a guanyl cyclase protein 
signaling cascade, which in turn elevates intracellular cyclic guanosine monophosphate 
(cGMP) levels, further activating a protein kinase G cascade and ultimately amplifying 
the pain signal in the STT neuron. NO may also react with superoxide and increase 
central pain sensitization and hyperalgesia [40]. 
When an electrical stimulus is applied, mechanoreceptive Aβ neurons are 
activated and accompanied by a localized tingling, “buzzing” sensation known as 
paresthesia. As Aβ signaling increases, the ratio of large-fiber to small-fiber activity 
increases, activating an inhibitory interneuron synapsing to the ascending ST neuron and 
ultimately weakening the pain signal to the brain [41]. 
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Figure 1.5: Gate Control Theory for Modulating Pain. A. Unmodulated (normal) 
pain: Peripheral pain signals travel up afferent C fibers to the CNS where they stimulate a 
second-order ST neuron and inhibit suppression by the inhibitory interneuron. B. 
Modulated pain: Neurostimulation stimulates afferent Aβ fibers parallel to afferent pain 
fibers in the CNS, resulting in the activation of an inhibitory interneuron and a 
suppressed pain signal to the thalamus [42]. 
 
Simultaneous to the reduction in pain sensation, the effect of the metaboreflex 
may be reduced. Normally, the metaboreflex is triggered by ischemic by-products such as 
adenosine and potassium which stimulate intramuscular chemoreceptors that send signals 
to type C fibers. Inhibition of type C small-fiber afferent signals by simultaneous Aβ 
activation would decrease the strength of the metaboreflex, resulting in a systemic 
decrease in vascular resistance [43]. Interestingly, the vasodilatory effect of 
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neurostimulation is likely stronger in PAOD patients than in healthy individuals. PAOD 
increases sympathetic activation as evidenced by increased concentrations of ischemic 
by-products and mean blood pressure (MBP) in response to exercise [44].  
 Endogenous opiate release may also be effected by neurostimulation. Β-endorphin 
levels increase in the lumbar cerebrospinal fluid (CSF) with low-frequency stimuli, 
resulting in an antinociceptive effect [45]. These effects were reversed by naloxone, 
indicating that low-frequency analgesia is mediated by micro-opioid receptor activity 
[46]. Interestingly, high-frequency TENS results in increased dynorphin A levels in the 
CSF with analgesic effects that are not reversed by naloxone, implicating dynorphin-
binding receptor activity [45]. These results indicate a frequency-dependent endogenous 
response to neurostimulation. 
1.2.2.2 Modulating Blood Flow and Ischemic Pain: α-2A Receptor Activation 
 It is also postulated that neurostimulation increases blood flow and decreases pain 
in the periphery via a second Aβ fiber pathway. Although the mechanism is unclear, 
ganglial stimulation of Aβ fibers initiates an efferent action potential that propagates 
down to α-2 adrenergic receptors (α-2A-Rs) in vascular sympathetic neuron terminals. 
These receptors are responsible for presynaptic inhibition of smooth muscle contraction 
by inhibiting norepinephrine (NE) release from sympathetic nerve terminals, Figure 1.6. 
α-2A-Rs are coupled to N-type calcium (Ca2+) channels in SNS neuron terminals, and 
activation reduces Ca2+ influx and subsequently decreased SNARE complex activity. 
Less norepinephrine (NE) is released into the synaptic cleft, and the interrupted 
sympathetic neuron signaling decreases vasoconstriction in the affected tissues and 
ultimately increases blood flow and reduces ischemic pain [47]. 
11 
 
 
 
Figure 1.6: α-2A Receptor Activation. Activation of α-2 adrenergic receptors causes 
presynaptic inhibition of signal transmission due to suppressed neurotransmitter (i.e. 
norepinephrine, NE) release [47]. 
 
 Interestingly, neurostimulation may have a time-sensitive effect that does not 
immediately present but extends beyond the period of stimulation itself, termed the 
“carry-over” effect. Evidence suggests that while TENS does not improve time to onset 
of ischemic pain, pre-treatment with TENS increases local blood flow and improves 
exercise tolerance at later time points [48]. Although the mechanism is unclear, it is 
possible that the carry-over effect may be associated with latencies in cellular activation. 
 In the context of PAOD, increased blood flow to ischemic peripheral tissues 
resulting from α-2A receptor activation would also reduce ischemic pain. In this way, 
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neurostimulation may have an additive analgesic effect in occluded tissues by 
simultaneously closing the pain gate and alleviating peripheral ischemia, Figure 1.7. 
 
 
 
Figure 1.7: Effects of Neurostimulation on Pain and Blood Flow. Stimulation of Aβ 
fibers has two effects: closing the pain gate in the central afferent pathway and activating 
α-2A receptors in the peripheral efferent pathway. Both pathways result in decreased pain 
and sympathetic control and ultimately increased blood flow. 
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1.2.3 Justification for the Use of TENS and IFC 
 A combination TENS/IFC transcutaneous neurostimulation device was chosen for 
the study because of its low cost and non-invasiveness, though the methodologies for 
investigating changes in peripheral perfusion associated with neurostimulation proposed 
by our study may translate to future research associated with implantable technology such 
as SCS. To our knowledge, there have been no previous studies directly comparing the 
hemodynamic effects of TENS and IFC, although studies with similar protocols have 
investigated each individually [34, 49, 50, 32, 51, 52]. Although both types of stimulation 
are known to effect pain and blood flow, the waveform and frequency settings have not 
yet been optimized for all possible indications. 
1.2.4 Waveform Characteristics 
 The two current waveforms most often used to study the analgesic effects of 
transcutaneous neurostimulation are biphasic pulsed currents characteristic of 
transcutaneous electrical nerve stimulation (TENS) and burst-modulated, sinusoidal 
alternating currents characteristic of interferential current (IFC) [53, 54]. More 
specifically, two out-of-phase sine waves combine to produce an IFC, Figure 1.8 [55]. 
These two waveforms are also used in implantable SCS therapies, with conventional SCS 
utilizing a symmetric pulsatile current similar to TENS while more contemporary 
therapies utilize burst-mode currents similar to IFC [56]. 
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Figure 1.8: TENS and IFC Stimulus Waveforms. A. Biphasic pulsed current 
characteristic of conventional TENS. B. Sinusoidal burst-modulated alternating current 
characteristic of IFC [29]. 
 
 Since membrane properties such as voltage-gated ion channel density, input 
resistance, capacitance, and synaptic contacts vary considerably between different neuron 
types and substructures (e.g. C fiber vs. Aβ fiber, axon vs. soma), it is likely that a 
waveform-dependent response exists [57, 58]. Conventional pulsatile current, such as in 
TENS, contains broad spectral energy that may limit the ability to preferentially activate 
neuronal targets, while narrow band sinusoidal waveforms, such as in IFC, may provide 
greater selective control [59]. Indeed, symmetrical charge-balancing stimuli greatly 
diminish selectivity in stimulating targeted neurons within the CNS, while asymmetrical 
biphasic stimuli enable selective activation of cells [60]. What is more, sinusoidal IFC 
waveforms may more readily overcome skin impedance and stimulate deeper Aβ fibers 
than pulsed TENS and therefore have greater analgesic and hyperemic effects [49, 61, 
62]. It is also possible that burst-modulated currents have a different effect than 
symmetrically pulsed currents, as well as high versus low frequencies [63]. Indeed, 
different endogenous signaling mechanisms occur during SCS with burst mode versus 
tonic mode stimuli [56] as well as with high (100 Hz) versus low (20 Hz) stimulus 
frequencies [46]. 
A B 
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 Although there is significant evidence that both TENS [32, 62, 64, 65, 66, 67] and 
IFC [68, 69, 49] effectively reduce experimentally induced pain, there is limited research 
comparing high and low frequency TENS and IFC treatments in their efficacy in 
increasing blood flow. However, there is little consensus in studies attempting to 
characterize changes in pain or blood flow by stimulus frequency or waveform [50]. 
Rather, optimal settings of stimulus parameters are subjective and are determined by trial 
and error [70].  
1.3 OVERVIEW AND SPECIFIC AIMS 
1.3.1 Overview 
 Neurostimulation may offer an innovative treatment option for patients suffering 
from PAOD. To date, there is no consensus on the effectiveness of different types of 
neurostimulation on modulating blood flow and pain in ischemic tissues, though it is 
believed that electrical stimulation decreases thalamus activity and sympathetic control of 
vascular tone by activating Aβ fibers. The focus of our study is to investigate 
hemodynamic and analgesic responses to transcutaneous neurostimulation during 
ischemia by performing a small scale clinical study and optimizing methodologies and 
protocols. 
1.3.2 Specific Aims 
The specific aims of this thesis are as follows: 
 Aim 1: Develop and optimize a protocol for investigating hemodynamic and 
analgesic responses to transcutaneous neurostimulation during acute ischemia in 
young, healthy Cal Poly students through exploring stimulus waveforms and 
frequencies during pilot studies. 
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 Aim 2: Test the hypothesis that transcutaneous electrical neurostimulation 
(TENS) and interferential current (IFC) treatments at the ganglia would result in 
decreased pain and vascular resistance in the periphery in young, healthy subjects.  
 Aim 3: Test the hypothesis that IFC has a greater hyperemic and analgesic effect 
on acute ischemia than TENS due to differences in stimulus current waveforms. 
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CHAPTER 2: PILOT WORK 
 
2.1 INTRODUCTION 
The overall goal of the pilot work was to develop and optimize a protocol for 
investigating hemodynamic and analgesic responses to transcutaneous neurostimulation 
during acute ischemia in young, healthy subjects. Therefore, the goals of the first pilot 
study were to ensure that our blood flow measurement instrumentation was functioning 
as expected, i.e. reporting zero perfusion during occlusion and hyperemia during 
recovery, and to optimize the neurostimulation frequency to elicit elevated perfusion and 
decreased pain during occlusion. Endogenous pain control mechanisms may be affected 
differently by high versus low stimulus frequencies [45, 46] and therefore we 
hypothesized that high (100 Hz) TENS and IFC stimulation frequencies would increase 
blood flow and analgesia during acute experimental pain in healthy subjects compared to 
low frequencies (20 Hz).  
After determining optimal instrumentation settings and neurostimulation 
frequency parameters in pilot study I, pilot studies II, III, and IV tested the hypothesis 
that neurostimulation has analgesic and hyperemic effects, possibly elevated with IFC as 
compared to TENS due to different effects of biphasic and sinusoidal stimulus 
waveforms on Aβ fibers [56]. After observing no noticeable differences in analgesic 
trends associated with TENS and IFC during pilot study II, pilot studies III and IV 
utilized multiple pain scales to better quantify sensations of pain experienced as a result 
of arterial occlusion. The additional pain scales gave insight that neurostimulation 
paresthesia was being perceived as a painful stimulus by the otherwise healthy subjects. 
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For this reason, pilot study IV accounted for sensations of paresthesia by including 
paresthesia descriptors in the general pain assessments. In this way, each consecutive 
pilot study served to refine our hypotheses and methodologies for the main investigative 
study. 
All participants completed an Informed Consent form and a confidential Medical 
History Questionnaire that was reviewed by the primary researcher prior to treatment. 
Any contraindications for transcutaneous neurostimulation, i.e. pregnancy or history of 
epilepsy, cardiovascular disease, dermatitis, syncope, or chronic pain, were grounds for 
exclusion, though no participants were excluded during any pilot work. All recruitment 
and experiments were performed in accordance with protocols approved by Cal Poly’s 
Human Subjects Committee. 
2.2 PILOT STUDY I 
2.2.1 Methods 
Pilot study I was performed on 12 healthy Cal Poly students aged 18 to 23 years 
assigned to one of two treatment groups: TENS (n=6) and IFC (n=6). Each group 
received three treatments: high frequency (100 Hz), low frequency (20 Hz), and sham (0 
Hz) neurostimulation, all involving 50 µs pulses at 8 mA pulse amplitude. 
Neurostimulation leads were always applied to the participant’s back regardless of 
treatment to maintain a single-blinded study. The participant was never notified of the 
treatment that was being applied, and all sensors and cuffs were applied in the same 
manner for every treatment. Treatment order was randomized and treatments were 
performed consecutively with a 10-minute rest period allotted between trials to minimize 
fatigue.  
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The cell bodies of Aβ fibers that innervate the arms and hands form ganglion 
parallel to the 7th cervical and 4th thoracic vertebrae (C7 and T4, respectively). The 
modulatory effects of TENS and IFC on pain and blood flow are substantiated when the 
electrodes are placed over the C7 and T4 ganglion rather than over the active muscles of 
the hand and forearm [unpublished observations]. Therefore, two pairs of 
neurostimulation electrodes (InTENSity TENS/IFC Combination Stimulator, Current 
Solutions LLC, Austin, TX, USA) were aligned with the C7 and T4 vertebrae on either 
side of the spinal column in a quadripolar formation using re-usable carbon electrode 
pads (Tyco Gel Pads, Santamedical, Tustin, CA, USA). Participants wore a loose shirt or 
tank top to allow access to the upper back, Figure 2.1. 
 
   
Figure 2.1: Electrode Placement. A. Topical electrodes were aligned with the C7 and 
T4 vertebrae for ganglial stimulation [32]. B. Participants wore loose clothing to allow 
access for electrode placement in a quadripolar formation.  
 
A B 
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 Two of the most prevalent methods for experimentally inducing pain are the 
submaximal tourniquet technique and the cold pressor test, both of which cause 
decreased blood flow to the effected tissues. We chose to use the tourniquet technique as 
it takes effect quicker and had a more rapid reperfusion rate after releasing the occlusion 
[71, 65, 68, 69], allowing for a more efficient protocol. Therefore, ischemic conditions 
similar to PAOD were modeled in otherwise healthy subjects using a 
submaximal tourniquet technique whereby a manual blood pressure cuff was inflated to 
180 mmHg for 3 minutes on the dominant forearm. To test the hypothesis that 
neurostimulation increases perfusion associated with acute ischemia, we measured 
changes in local blood flow (BF) distal to the occlusion and mean arterial pressure (MBP) 
on the contralateral arm.  
At the start of each treatment session, participants sat in a relaxed position with 
their arms resting on a tray. An automated blood pressure cuff (Omron 7 Series Wireless 
Upper Arm Blood Pressure Monitor, BP761, Hoffman Estates, IL, USA) was applied to 
the contralateral upper arm to measure MBP and HR every 3 minutes as specified in the 
monitor’s instructions for use on timing. After attaching the electrodes to the upper back, 
an optic Laser Doppler Flowmetry (LDF) skin probe (VP1 probe, Moor Instruments, 
Wilmington, DE, USA) was adhered to each palm using double sided adhesive (PADs, 
Moor Instruments). A hand grip dynamometer (ADInstruments, Colorado Springs, CO, 
USA) was gripped in the dominant hand. The probe cables coupled to a LDF data 
acquisition unit (moorVMS-LDF, Moor Instruments), which output to a PowerLab DAQ 
(PowerLab, ADInstruments) and digital chart recording software (LabChart 8.0, 
ADInstruments) Figure 2.2.  
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The hyperemic and analgesic effects of each treatment type were evaluated during 
the pressor response to static handgrip exercise at 30% maximal voluntary contraction for 
3 minutes followed by a 3 minute occlusion. Change in distal blood flow and pain from 
resting baseline values were evaluated before, during, and after exercise and occlusion. 
This temporary circulatory occlusion in young healthy subjects was an imperfect 
approximation to PAOD as chronically ischemic tissues have depleted adenosine 
triphosphate (ATP) and glycogen stores, as well as elevated levels of metabolic 
byproducts such as lactate, which hinder rapid reperfusion (i.e. reactive hyperemia) once 
the occlusion is removed [72]. PAOD patients will also have tremendous endothelial 
dysfunction as compared to healthy young subjects, hindering their vasculature’s 
capability to respond to stimuli. Therefore, we would expect the reperfusion rates 
observed in response to our experimentally induced ischemia to be faster than in PAOD 
patients. 
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Figure 2.2: Experimental Setup. A. Participants sat in a relaxed position with arms 
resting on the tray in a prone position. Optic Laser Doppler Flowmetry (LDF) skin probes 
(a) were adhered to each palm using double sided adhesive. A manual BP cuff (b) was 
affixed to the participant’s dominant forearm to occlude the treatment hand. A hand grip 
dynamometer (c) was gripped in the dominant hand. An automated BP monitor was 
affixed to the upper contralateral arm (d) and the TENS/IFC unit (e) electrodes were 
placed on the upper back. B. The probe cables coupled to a moorVMS-LDF data 
acquisition unit (f) which connected to a PowerLab DAQ (g) via two analog inputs. The 
LDF signals were transmitted to a laptop via USB cable and recorded in real time using 
LabChart v.8 software. 
 
The Numeric Rating Scale (NRS) was used to assess pain on a scale of 0 – 10 
every 60 seconds, 0 being no pain and 10 being the worst pain imaginable. The maximum 
pain was reported for each 60 second interval and raw hemodynamic data was averaged 
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for 60 second intervals during each phase. Although both absolute change and percent 
change models were run for both responses, absolute change had more statistical power 
(higher R2) for analyzing this pain and blood flow dataset and therefore all results are 
reported in terms of absolute change from baseline. Blood flow and pain responses were 
compared to phase, ischemic conditions, and treatment type by two-way ANOVA for 
repeated measures using Minitab statistical software. Post hoc comparisons were made 
using Tukey-Kramer’s intervals. 
2.2.2 Results 
2.2.2.1 Pain 
As expected, pain trended to increase during occlusion. However, 
neurostimulation did not appear to have an analgesic effect as predicted; to the contrary, 
pain trended to be greater with both high and low frequency TENS and IFC treatments at 
each phase than the sham treatment, Figure 2.3. 
 
 
Figure 2.3: Change in Pain for Pilot Study I. Change in pain from baseline during A. 
High (100 Hz) and low (20 Hz) frequency TENS and B. High (100 Hz) and low (20 Hz) 
frequency IFC (n=6). Values are shown as mean ± SE. *p≤0.05 for ∆pain vs. phase. 
* 
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2.2.2.2 Blood Flow 
As expected, blood flow increased in the palm during exercise and during the 
recovery phase following an acute forearm occlusion. There were no differences in blood 
flow between high and low frequency TENS treatments, though perfusion was lower 
during the recovery phase of the high frequency IFC treatment, Figure 2.4.  
 
 
Figure 2.4: Change in Blood Flow for Pilot Study I. Change in blood flow from 
baseline during A. High (100 Hz) and low (20 Hz) frequency TENS and B. High (100 
Hz) and low (20 Hz) frequency IFC (n=6). Values are shown as mean ± SE. *p≤0.05 for 
∆blood flow vs. phase. 
 
2.2.3 Discussion 
To test the hypothesis that high (100 Hz) TENS and IFC stimulation frequencies 
increase blood flow and analgesia more so than low frequencies (20 Hz), pilot study I 
compared changes in blood flow and pain elicited by both modalities before, during, and 
after acute ischemia. Both TENS and IFC had a hyperalgesic effect during exercise, 
occlusion, and recovery, Figure 2.3. This result is not substantiated by the main body of 
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research emphasizing the analgesic effects of transcutaneous neurostimulation. It is 
possible that paresthesia associated with the vibrational mechanoreception of 
neurostimulation near the ganglia was interpreted by first-time neurostimulation users as 
“pain,” creating arbitrarily high pain measurements with TENS and IFC treatments. In 
subsequent studies, participants will be instructed to concentrate on pain originating 
exclusively in their treatment arm to promote specificity. 
The increase in local blood flow during exercise and immediately following the 
release of an upstream occlusion, Figure 2.4, may be explained by metabolic 
vasodilation and reactive hyperemia, respectively. Metabolic byproducts released during 
exercise cause vascular smooth muscle cells to relax, resulting in vasodilation and 
increased blood flow. These byproducts also activate the metaboreflex, which in turn 
selectively inhibits sympathetic vasoconstriction in active tissues in a process known as 
functional sympatholysis. Reactive hyperemia, or the rapid increase in perfusion 
following ischemia, is attributed to the release of local vasodilator metabolites in hypoxic 
tissues.  
We hypothesized that neurostimulation activates peripheral α-2 adrenergic 
receptors, inhibiting norepinephrine release and decreasing local sympathetic tone [73]. 
This results in an increase in blood flow independent of functional sympatholysis or 
reactive hyperemia. However, at this sample size (n=6), we did not see sufficient 
evidence that neurostimulation has a hyperemic or an analgesic effect. Moving forward, a 
larger sample size would allow us to improve our predictive power. We must also control 
for vasodilation mediated by local metabolites following ischemia. To isolate TENS or 
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IFC-induced hyperemia from metabolically-induced hyperemia, pilot study II will 
incorporate a control treatment without post-exercise occlusion (PECO-).  
Since there were no significant differences in pain or blood flow between 100 Hz 
and 20 Hz frequencies for either TENS or IFC treatment, future work will use a standard 
100 Hz frequency to control for possible effects of frequency on Aβ fiber activation 
similar to frequency settings used in comparator studies [51, 32].  
2.3 PILOT STUDY II 
2.3.1 Methods 
Pilot study II was conducted on 9 healthy Cal Poly students age 18-23. 
Treatments were blinded, randomized, and followed by 10-minute rest periods. TENS 
and IFC settings were standardized for every treatment at 100 Hz frequencies, though the 
main protocol for pilot study II closely followed pilot study I. 
Study II controlled for the metaboreflex by selectively applying the occlusion and 
comparing trends in blood flow with (PECO+) and without (PECO-) ischemia. A blocked 
experimental design was used to evaluate both TENS and IFC treatments in relation to a 
placebo (sham) treatment. Each participant received a total of six treatment combinations: 
TENS, PECO+; TENS, PECO-; IFC, PECO+; IFC, PECO-; placebo, PECO+; and 
placebo, PECO-. Completing all six treatment types on the same individual allowed us to 
control for differences in neural and cardiovascular physiology between subjects. 
 Furthermore, pilot study II individualized the intensity of the neurostimulation for 
every treatment session to account for differences in pain tolerances between participants. 
At the beginning of each treatment, the stimulus amperage was increased from 0 mA to 
the subject’s personal pain tolerance threshold, then dropped 1 mA and held constant 
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throughout the rest of the session. If the motor threshold was reached before the pain 
threshold such that involuntary muscle twitching occurred, as seen in 2 of the 9 subjects, 
the intensity was dropped to 1 mA below motor threshold.  
Hemodynamic and pain responses were measured and analyzed similarly to pilot 
study I. Absolute change and percent change models were run for both responses and 
percent change had more statistical power (higher R2) for change in blood flow with the 
pilot study II dataset. Therefore, pain data was analyzed in terms of absolute change 
while blood flow data was analyzed in terms of percent change. Two-way ANOVA for 
repeated measures and Tukey-Kramer post hoc analysis were completed in Minitab. 
2.3.2 Results 
2.3.2.1 Pain 
 Similar to the trends in pilot study I, NRS pain trended to increase during exercise 
and when occlusion was applied (Placebo+, TENS+, IFC+). Indeed, pain increased each 
successive minute during occlusion (t=6-9 min), Figure 2.5. In contrast to pilot study I, 
both TENS and IFC treatments trended to lower ischemic pain during occlusion in pilot 
study II, Figure 2.6. 
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Figure 2.5: Absolute Pain across Time during Pilot Study II. Absolute pain every 
minute during baseline, exercise, occlusion, and recovery phases for each treatment 
combination (n=9). Values are shown as mean ± SE. *p≤0.05 for ∆pain vs. time. 
  
 
Figure 2.6: Change in Pain during Pilot Study II. Change in mean pain (n=9) from 
baseline over A. Time (Baseline, Exercise, Occlusion, and Recovery phases), B. 
Neurostimulation type (IFC, Placebo, TENS), and C. Ischemia (PECO-, PECO+). 
*p≤0.05 for ∆pain vs. time, neurostimulation treatment, & ischemia.  
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2.3.2.2 Blood Flow 
 As expected, blood flow increased during exercise, decreased during occlusion 
(+), and increased during recovery following occlusion, Figure 2.7A. When occlusion is 
not applied, blood flow increases during exercise and remains above baseline for the 
following 9 minutes, Figure 2.7C. Interestingly, blood flow increased in the contralateral 
arm with IFC treatment during occlusion and remained elevated during recovery, Figure 
2.7B, while without occlusion there was no difference in blood flow with IFC treatment, 
Figure 2.7D. Another interesting trend was seen in contralateral blood flow with TENS 
treatment, as TENS increased blood flow during exercise while IFC and placebo 
treatments did not (confidence interval included 0 %∆), Figure 2.7B,D. 
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Figure 2.7: %Change in Blood Flow during Pilot Study II. Percent change in blood 
flow from baseline during exercise, occlusion, and recovery phases with TENS (n=9) and 
IFC (n=9) with occlusion (PECO+) in the A. treatment (dominant) and B. contralateral 
hands, and without occlusion (PECO-) in the C. treatment and D. contralateral hands. 
Values are shown as mean ± SE. *p≤0.05 for %∆blood flow vs. phase. 
 
2.3.3 Discussion 
 To test the hypothesis that TENS and IFC stimulation have different effects on 
perfusion and analgesia, pilot study II compared changes in blood flow and pain elicited 
by both modalities before, during, and after acute ischemia. In contrast to hyperanalgesic 
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trends seen in pilot study I, pilot study II showed analgesic trends associated with both 
TENS and IFC during occlusion as predicted, Figures 2.5, 2.6. We also saw that 
ischemic pain increased in severity in a similar manner for placebo, TENS, and IFC 
treatments the longer the occlusion was maintained, though the maximal change in pain 
was relatively low on the NRS pain scale.  
 It is possible that the analgesic effects of neurostimulation are more pronounced 
with chronic pain in diseased patients than with acute experimental pain in healthy 
patients [38]. Instead, future studies will evaluate pain in a quantitative manner using the 
Numeric Rating Scale (NRS) as well as in a qualitative manner using the Faces and Short 
Form McGill Pain Questionnaire (SF-MPQ) scales, Appendices H, I. This may help to 
better measure changes in uncomfortable sensations at lower pain stimulus intensities. 
 The increase in blood flow observed during recovery when occlusion was applied 
(+ treatments) and static blood flow observed when occlusion was not applied (- 
treatments), Figure 2.7, supports the hypothesis that reactive hyperemia is independent of 
electrical stimulation. Additionally, the observed differences in blood flow with TENS 
during exercise and with IFC during occlusion indicate that pulsed biphasic and burst-
modulated alternating stimulus waveforms may have different effects on blood flow.  
 However, there was no evidence that TENS or IFC had an overall analgesic or 
hyperemic effect independent of metabolic demands. Healthy young subjects (n=11) 
similar to our study population have shown increased calf blood flow with local TENS 
treatment at rest, during exercise, and during occlusion as compared to placebo treatment 
[32], Figure 2.8, supporting the hypothesis that neurostimulation can increase blood flow 
through a secondary mechanism such as Aβ fiber activation.  
32 
 
 It is possible that electrodes were not consistently placed over the C7 and T4 
ganglion during each trial, resulting in an arbitrarily high type II error in our pain and 
blood flow results. To improve consistency, electrode pads will not be removed from the 
participant’s back during the resting period between trials. The accuracy of electrode 
placement will also be improved by receiving instruction from a licensed physical 
therapist on how to palpate for the C7 and T4 vertebrae prior to attaching the electrode 
pads to the skin. 
 
  
Figure 2.8: %Change in Calf Blood Flow in Comparator Study. TENS treatment 
increased blood flow regardless of exercise or ischemia in healthy young subjects similar 
to our study population [32]. Values are shown as mean ± SE. *p≤0.05 for %∆CBF vs. 
time. 
2.4 PILOT STUDY III  
2.4.1 Methods 
 Pilot study III focused on expanding our pain measurement techniques. A 
protocol very similar to pilot study II was performed on 9 healthy Cal Poly students age 
%
∆
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18-23. Treatments were blocked by neurostimulation (TENS/placebo) and occlusion 
(PECO+/PECO-) and performed in a randomized, single-blinded manner. Pain was 
assessed at 60 second intervals using both quantitative and qualitative pain scales: the 
Numeric Rating Scale (NRS) and Faces scale, respectively, Appendix H. Participants 
verbalized their numeric pain on a scale of 0 – 10, and then identified which face (A – G) 
best described their pain. Lettered scores were assigned weights of 0 – 6, respectively, for 
quantitative analysis. A SF-MPQ was administered orally halfway through both the 
exercise phase and the occlusion phase with the participant rating each descriptor as 
‘none, mild, moderate, or severe,’ Appendix I. These qualitative scores were assigned 
weights of 0, 1, 2, and 3, respectively, for quantitative analysis, Figure 2.9.  
 
 
Figure 2.9: Sample Pain Measurement Consolidation and Normalization. NRS and 
Face pain measurements were consolidated down into one summary value for each phase. 
The NRS values were summed for both the E and O phases and the sum recorded as the 
absolute pain measurement for that phase. The Face letters were assigned numerical 
weights (A=0, B=1, C=2, ect.) and the highest weight recorded for each phase. The 
absolute values were then normalized to the baseline values by taking the difference 
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between that phase and baseline. The normalized values were used for quantitative 
analysis. 
2.4.2 Results 
 All three scales show the same trends in pain for each neurostimulation type, 
Figures 2.10, 2.11, 2.12. As expected, pain increased with occlusion. However, pain 
trends observed during TENS treatments were no different than trends observed during 
placebo treatments. 
 
 
Figure 2.10: Mean Change in Pain during Pilot Study III Using the NRS Pain Scale. 
Change in average pain compared across A. Subject (n=9), B. Neurostimulation (TENS, 
Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and without 
ischemia (P-, P+, T-, T+). 
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Figure 2.11: Mean Change in Pain during Pilot Study III Using the Faces Pain 
Scale. Change in average pain compared across A. Subject (n=9), B. Neurostimulation 
(TENS, Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and 
without ischemia  
(P-, P+, T-, T+). 
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Figure 2.12: Mean Change in Pain during Pilot Study III Using the MPQ Pain 
Scale. Change in average pain compared across A. Subject (n=9), B. Neurostimulation 
(TENS, Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and 
without ischemia  
(P-, P+, T-, T+). 
 
2.4.3 Discussion 
 Although the NRS, Faces, and MPQ pain scales used different schemes (numeric, 
associative, and descriptive, respectively) to quantify the intensity of ischemic pain, all 
three scales resulted in increased pain trends for TENS treatments. Interestingly, the exact 
same protocol that resulted in analgesic trends with TENS in pilot study II resulted in 
hyperalgesia in pilot study III. This inconsistency in results warrants a fourth pilot study 
to determine our ability to replicate our results before beginning a larger trial with an 
appropriately powered sample size. 
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2.5 PILOT STUDY IV 
2.5.1 Methods 
Pilot study IV was conducted in the same manner as pilot study III on 12 healthy 
Cal Poly students age 18-23. Treatments were blocked by neurostimulation 
(TENS/IFC/placebo) and occlusion (PECO+/PECO-) and performed in a randomized, 
single-blinded manner. Pain was assessed at 60 second intervals using the NRS and Faces 
scales and an SF-MPQ was administered during each phase. The SF-MPQ was modified 
to include 5 paresthesia descriptors in addition to the 25 pain descriptors to allow 
participants to identify both paresthesia and pain sensations associated with ischemia. 
2.5.2 Results 
2.5.2.1 Pain 
 As expected, occlusion (ischemia +) was correlated with an increase in pain both 
during ischemia and immediately following occlusion, Figure 2.13. Interestingly, 
neurostimulation itself was painful without occlusion (ischemia -) in the first few minutes 
after exercise, Figure 2.13A, but not at later time points (ischemia -), Figure 2.13B. 
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Figure 2.13: Mean Change in Pain during Pilot Study IV Using the MPQ Pain Scale. 
A. Pain increased during occlusion (ischemia +) for IFC, TENS, and Placebo treatments, 
though TENS and IFC caused an increased pain without occlusion (ischemia -). B. Pain 
increased during recovery following occlusion (ischemia +) for IFC, TENS, and Placebo 
treatments. 
 
2.5.2.2 Blood Flow 
 Hyperemic trends occurred with the release of an occlusion during the recovery 
phase, as expected. In pilot study II, both TENS and IFC amplified hyperemic trends 
compared to placebo treatments, possibly supporting the hypothesis that neurostimulation 
has a hyperemic effect in ischemic tissues, Figure 2.14A. However, TENS and IFC 
trended similarly to placebo treatments in pilot study IV, Figure 2.14B. 
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Figure 2.14: Comparison of Mean ΔBlood Flow during Recovery for Pilot Study II 
and IV. Blood flow increased following occlusion (ischemia +) for IFC, TENS, and 
Placebo treatments. ΔBlood flow A. During pilot study II showed a greater hyperemic 
trend with IFC and TENS treatments, while B. During pilot study IV all three treatments 
trended similarly. 
 
2.5.3 Discussion 
Including paresthesia in our pain measurements allowed us to better quantify 
paresthesias being interpreted as painful stimuli by subjects using TENS and IFC. 
Paresthesia significantly increased “pain” in resting, non-occluded tissues with 
neurostimulation treatments as compared to placebo treatments in the 4th-6th minutes of 
the protocol (“occlusion phase”) but not in the 7th-9th minutes (“recovery phase”). It is 
possible that peripheral nociceptors adapted to paresthesia such that participants felt the 
sensation at earlier time points but not later time points. 
It is also possible that the static handgrip exercise itself was painful, resulting in 
increased pain sensations in the 3 minutes immediately following exercise that subsided 
over time [74]. To reduce pain associated with the handgrip exercise, we will procure to a 
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more ergonomic hand dynamometer (iWorx, San Luis Obispo, CA, USA) for the clinical 
study. 
 Although there were no statistically significant differences in blood flow observed 
with neurostimulation, the exaggerated hyperemic trends associated with TENS and IFC 
seen in pilot study II were not duplicated in pilot study IV. While these trends are not 
consistent between the two pilot studies, we must increase our statistical power before 
confident conclusions can be made. To this effect, our clinical study will use a much 
larger sample size than the pilot studies with the goal of finding a definitive effect of 
neurostimulation on perfusion. Sample size will be determined by a power analysis using 
the pain and blood flow data variability observed between subjects in pilot study IV. 
Furthermore, instead of looking at only blood flow measurements, we will account for 
SNS control of systemic perfusion by incorporating blood pressure measurements. 
Moving forward, whole-limb perfusion will be evaluated in terms of vascular 
resistance (∆𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 = ∆𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒/∆𝐹𝑙𝑜𝑤). We will also control for caffeine, a 
known vasoconstrictor, to more accurately evaluate sympathetically-mediated changes in 
vascular tone. 
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CHAPTER 3: CLINICAL STUDY 
 
3.1 INTRODUCTION 
3.1.1 Proposed Hemodynamic Mechanism of TENS and IFC 
 The main body of research involving TENS and IFC focuses on their analgesic 
effects on neuromuscular pain, which can be explained by the gate control theory. 
However, it is also postulated that neurostimulation increases blood flow to the 
peripheries via a related pathway. In the context of PAOD, increased blood flow to 
ischemic peripheral tissues should also reduce pain, resulting in an additive analgesic 
effect. This focus of this study is to investigate hemodynamic responses to 
neurostimulation during acute ischemia. Although the mechanism is unclear, electrical 
stimulation may suppress local sympathetic tone and ischemic pain by activating Aβ 
fibers (large-diameter) parallel to the nociceptive C fibers (small-diameter) in the dorsal 
horn. Ganglial stimulation of Aβ fibers initiates an efferent action potential that 
propagates down to α-2 adrenergic receptors (α-2A-Rs) in vascular sympathetic nerve 
terminals. α-2A-Rs are coupled to voltage-dependent N-type calcium channels via a G 
protein. α-2A-R activation inhibits calcium influx responsible for presynaptic 
norepinephrine release, resulting in localized vasodilation and ultimately increased blood 
flow and reduced ischemic pain in the affected tissues [73]. 
3.1.2 Study Aims and Hypotheses 
To our knowledge, there have been no previous studies directly comparing the 
hemodynamic effect of TENS and IFC, although studies with similar protocols have 
investigated each individually [32, 52]. The main goal of the preclinical work was to 
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develop protocols for investigating changes in vascular resistance and perceived pain 
elicited by both neurostimulation techniques and to a placebo (control) treatment. 
 We hypothesized that transcutaneous neurostimulation will increase blood flow 
and decrease vascular resistance, possibly due to a decrease in sympathetic activity. This 
may occur both indirectly from a decrease in metaboreflex activation and directly from 
selective inhibition of norepinephrine release. 
 Additionally, we hypothesize that TENS and IFC neurostimulation modalities will 
have differing effects on blood flow and vascular resistance. It is possible that the 
sinusoidal waveform in IFC may more readily overcome skin impedance than the 
biphasic pulsed waveform characteristic of TENS and thus have a more significant effect 
on the Aβ afferent fibers, resulting in a greater inhibitory effect on pain and sympathetic 
tone. We further hypothesized that IFC may have a greater hyperemic effect than TENS 
as its current waveform may be more efficient at overcoming skin impedance. Lastly, we 
hypothesize that vascular resistance will inversely correlate to ischemic pain, Table 3.1. 
 
Table 3.1: Expected Trends for Hemodynamic Factors and Pain during Recovery. 
Expected Outcome 
Placebo TENS IFC 
PECO- PECO+ PECO- PECO+ PECO- PECO+ 
Heart Rate - - ↓ ↓↓ ↓ ↓↓ 
Skin Temperature - ↑ ↑ ↑↑ ↑ ↑↑ 
Mean Blood Pressure - ↓ ↓ ↓↓ ↓ ↓↓ 
Local Blood Flow - ↑ ↑ ↑↑ ↑ ↑↑ 
Contralateral Blood Flow - ↑ - ↑↑ - ↑↑ 
Vascular Resistance - ↓ ↓ ↓↓ ↓ ↓↓ 
Ischemic Pain - ↓ ↓ ↓↓ ↓ ↓↓ 
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3.2 STUDY PARTICIPANTS 
The preclinical study was performed on 45 healthy Cal Poly students aged 18 to 
23 years. All participants completed an Informed Consent form (Appendix A), a Medical 
History Questionnaire (Appendix B), and a W9 Tax Form (Appendix C), prior to 
treatment, the latter for acquiring participant compensation in the form of a $25 Visa gift 
card. These forms, along with all hemodynamic and pain data, were kept confidential 
with the exception of the W9 form which was submitted to the Sponsored Programs 
department.  
The Medical History Questionnaire was reviewed by the primary researcher prior 
to starting treatment. Any contraindications for transcutaneous neurostimulation, i.e. 
pregnancy or history of epilepsy, cardiovascular disease, dermatitis, syncope, or chronic 
pain, were grounds for dismissal. Furthermore, participants fasted from caffeine for at 
least 12 hours prior to the treatment, as caffeine is a known vasoconstrictor. This 
information, as well as age and body mass data, was also collected on the Questionnaire. 
No participants were dismissed as a result of medical contradictions or non-compliance 
with fasting from caffeine. 
 All recruitment and experiments were performed in accordance with a protocol 
approved by the Cal Poly Human Subjects Committee. The petition for approval 
(Appendix D), Overview PowerPoint (Appendix E), and a detailed protocol (Appendix 
F) can be found in the appendices.  
3.3 MATERIALS AND METHODS 
 Similar to the pilot studies, the hypothesis that neurostimulation increases 
perfusion during acute ischemia was evaluated by measuring mean blood pressure (MBP) 
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and blood flow (BF) before, during, and after ischemia. These response variables were 
then combined into terms of vascular resistance (VR) to assess the conductive effect of 
neurostimulation (∆𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 = ∆𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒/∆𝐹𝑙𝑜𝑤). To test the hypothesis that 
neurostimulation diminishes sympathetic tone, we also measured heart rate (HR) as 
decreased HR would be indicative of decreased SNS activity. Since the stimulus is 
applied at the ganglion, we expected to see a similar decrease in SNS activity along the 
same dermatome in the contralateral limb. 
 Lead electrodes and their corresponding ground electrodes were aligned with the 
vertebrae approximately two inches from either side of the spinal column in a quadripolar 
formation, Figure 2.1. To ensure accurate electrode placement, participants wore a loose 
shirt or tank top to allow access to the upper back and the C7 and T4 vertebrae were 
identified via manual palpation. Participants sat in a relaxed position with their arms 
supinated and four neurostimulation leads (InTENSity TENS/IFC Combination 
Stimulator, Current Solutions LLC) were attached to the participant’s upper back with re-
usable carbon electrode pads (Tyco Gel Pads, Santamedical). Both the TENS and IFC 
treatments involved 50 µs pulses at a rate of 100 pps at intensities below the motor 
threshold (1-15 mA). An optic Laser Doppler Flowmetry (LDF) skin probe (VP1 probe, 
Moor Instruments) was adhered to each palm using double sided adhesive (PADs, Moor 
Instruments). The probe cables coupled to a LDF data acquisition unit (moorVMS-LDF, 
Moor Instruments), which output to a PowerLab DAQ and digital chart recording 
software (LabChart 8.0).  
 A skin thermistor (ADI Instruments) was taped to the palm before an ergonomic 
hand grip dynamometer (iWorx) was gripped in the dominant hand. Post-exercise 
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circulatory occlusion (PECO) mimicked acute ischemia, which is present in patients with 
PAOD, in otherwise healthy subjects by inflating a manual blood pressure cuff to 180 
mmHg on the forearm of the treatment arm for 3 minutes. An automated blood pressure 
cuff was applied to the contralateral upper arm to measure MBP and HR every 2.5 
minutes as specified in the monitor’s instructions for use (Omron 7 Series Wireless 
Upper Arm Blood Pressure Monitor, BP761), Figure 2.2. Data recordings were compiled 
into a master spreadsheet for later analysis, Appendix G.  
A crucial part of the experimental design was distinguishing between changes in 
vascular tone related to neurostimulation versus vasoactive reflexes such as the 
metaboreflex. To selectively induce acute ischemia and examine the effects of both 
TENS and IFC in relation to a placebo treatment, each treatment type was applied with 
(PECO+) and without (PECO-) vascular occlusion. A randomized blocked experimental 
design ensured that each participant received a total of six treatment combinations: 
TENS, PECO+; TENS, PECO-; IFC, PECO+; IFC, PECO-; placebo, PECO+; and 
placebo, PECO-. Neurostimulation leads were always applied to the participant’s back 
regardless of treatment type to help maintain a single-blinded study. The participant was 
never notified of which treatment type was being applied, and all sensors and cuffs were 
applied the same way for every treatment. Treatment order was randomized and 
treatments were performed consecutively. A 10-minute rest period was allotted between 
trials to minimize fatigue. The intensity of the neurostimulation was individualized for 
every session and held constant below the motor and pain thresholds.  
After familiarizing the participant with the monitoring equipment, pain scales, and 
protocol, a resting baseline was recorded for one minute, followed by three minutes of 
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handgrip exercise, Figure 3.3. Maximal handgrip force of the dominant hand was 
determined by the highest output obtained in three trials, each 1 second in duration. A 
static grip exercise at 30% of maximal grip force was then maintained for the remainder 
of the 3 minutes. Next, for PECO+ treatment types, the participant released the hand 
dynamometer and the blood pressure cuff on the treatment forearm was manually inflated 
to 180 mmHg for 3 minutes to induce ischemia in the treatment hand. For PECO- 
treatment types, the blood pressure cuff was not inflated and the participant released the 
dynamometer. At the 7th minute, the blood pressure cuff was released and a one minute 
recovery period was recorded. 
 
 
Figure 3.1: Protocol Flowchart. After the neurostimulation treatment type (placebo, 
TENS, or IFC) was turned on and the intensity adjusted to below the pain and motor 
thresholds, the 1 minute of baseline was recorded, followed by 3 minutes of static 
handgrip exercise, 3 minutes of PECO+/PECO-, and 1 minute of recovery. 
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 Pain was assessed at 60 second intervals using the Numeric Rating Scale (NRS) 
and Faces scale, Appendix H. A modified Short-Form McGill Pain Questionnaire (mSF-
MPQ), Appendix I, was administered halfway through both the exercise phase and the 
occlusion phase to allow participants to identify both paresthesia and pain sensations 
associated with ischemia.  
 Raw data was separated into four phases according to the experimental protocol: 
baseline, exercise, occlusion, and recovery, Figure 3.2. Hemodynamic responses were 
averaged for 30 second intervals during each phase and then expressed as an absolute 
change from the baseline value. All experimentally measured hemodynamic factors, 
including skin temperature (°C), respiratory rate (BPM), and local and contralateral blood 
flow (PU), were compared by two-way ANOVA for repeated measures while interactions 
between each factor and treatment phase and ischemia were compared by three-way 
ANOVA for repeated measures using JMP statistical software. Post hoc comparisons 
were analyzed using Tukey-Kramer’s method, Appendix M. 
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Figure 3.2: Raw Data Traces by Phase. The raw data traces were sectioned by phase 
and averaged for 30 second intervals for all experimentally measured hemodynamic 
factors including A. Skin temperature (°C), B. Respiratory rate (BPM), C. Grip force (N), 
D. Local blood flow (PU), E. Contralateral blood flow (PU). 
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3.4 DATA ANALYSIS 
3.4.1 Change in Vascular Resistance  
To examine the relationship between neurostimulation and perfusion under 
ischemic and non-ischemic tissue conditions, we first determined the importance of 
dependent study variables, including subject, treatment type, ischemia, and phase, on 
each other and on the average change in VR (∆𝑉𝑅̅̅ ̅̅ ) using two and three-way ANOVAs 
for repeated measures. Since the calculation for ∆𝑉𝑅̅̅ ̅̅  incorporates both flow and pressure 
measurements, ∆𝑉𝑅̅̅ ̅̅  is the best approximation of cutaneous perfusion and therefore is the 
response variable in our statistical analysis. ∆𝑉𝑅̅̅ ̅̅  was calculated as: 
∆𝑉𝑅̅̅ ̅̅ =
∆𝑀𝐵𝑃̅̅ ̅̅ ̅̅ ̅
∆𝐶𝐵𝐹̅̅ ̅̅ ̅̅
, [
𝑚𝑚𝐻𝑔
𝑃𝑈
] 
where 
∆𝑀𝐵𝑃̅̅ ̅̅ ̅̅ ̅ = ∆𝐷𝐵𝑃̅̅ ̅̅ ̅̅ +
∆𝑆𝐵𝑃̅̅ ̅̅ ̅̅ − ∆𝐷𝐵𝑃̅̅ ̅̅ ̅̅
3
, [𝑚𝑚𝐻𝑔] 
and 𝑃𝑈 is an arbitrary Perfusion Unit of Doppler velocimetry that approximates 
cutaneous blood flow.  
The ∆𝑉𝑅̅̅ ̅̅  dataset was left-skewed and required transformation to fit the criteria for 
normality in ANOVA testing. The data were rectified by adding 10 mmHg/PU to each 
∆𝑉𝑅̅̅ ̅̅ value and subsequently transformed using a base 10 logarithm. This transformed the 
data into a normal distribution for further statistical analysis. Thus, the experimental 
changes in perfusion were modeled using phase, treatment type, and ischemia as 
independent variables, subject as a random variable, and ∆𝑉𝑅̅̅ ̅̅  as the dependent response 
variable. The shorthand prediction expression is: 
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log10(VR+10) = ∆𝑉𝑅̅̅ ̅̅ ̅̅  + Phase + Treatment + Phase*Treatment + Ischemia + 
Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject 
This expression is written as a general linear model in the form:  
𝑦𝑖𝑗 = 𝜇𝑖𝑗 + 𝛼1 + 𝛼2 + 𝛼1𝛼2 + 𝛼3 + 𝛼1𝛼3 + 𝛼2𝛼3 + 𝛼1𝛼2𝛼3 + 𝜀𝑖𝑗 
where 
𝜇𝑖𝑗 = Average Change in Vascular Resistance (∆𝑉𝑅̅̅ ̅̅ ) 
𝛼1 =  {
𝛼𝐸
𝛼𝑂
𝛼𝑅
} = Effect of phase (E, O, or R) on ∆𝑉𝑅̅̅ ̅̅  
𝛼2 = {
𝛼𝑇
𝛼𝐼
𝛼𝑃
} = Effect of treatment type (TENS, IFC, or placebo) on ∆𝑉𝑅̅̅ ̅̅  
𝛼3 = {
𝛼𝑃𝐸𝐶𝑂+ 
𝛼𝑃𝐸𝐶𝑂− 
} Effect of ischemia (PECO+ or PECO-) on ∆𝑉𝑅̅̅ ̅̅  
𝜀𝑖𝑗 = Residuals, or errors around the predicted trendline 
This model allowed us to test the hypothesis that neurostimulation decreases 
vascular resistance. However, because the effects of treatment phase and ischemic 
conditions can impact the effects of TENS and IFC on perfusion, we evaluated the 
interactions between treatment type, treatment phase, and ischemia. We also accounted 
for between-subject variability by including subject in the model. 
Due to the complexity of the model, statistical signiﬁcance was accepted when p 
≤ 0.01. This allowed for only a 7% probability of falsely obtaining the observed effect in 
the sample data, assuming our model with 7 fixed input factors was reasonable. No data 
points were excluded as outliers, and it was reasonable to assume equal variance in the 
dataset (Levene: p > 0.05). The expanded prediction expression may be seen in 
Appendix J. 
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3.4.2 Change in Pain  
Pain data was analyzed for each pain scale in relation to subject, treatment type, 
ischemia, and phase using two and three-way ANOVAs for repeated measures. The 
experimental changes in pain were modeled as a function of phase, treatment type, 
ischemia, and subject. Statistical signiﬁcance was accepted when p ≤ 0.05. The shorthand 
prediction expression is: 
∆Pain = ∆𝑃𝑎𝑖𝑛̅̅ ̅̅ ̅̅ ̅̅  + Phase + Treatment + Phase*Treatment + Ischemia + 
Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject 
This expression is written as a general linear model in the form:  
𝑦𝑖𝑗 = 𝜇𝑖𝑗 + 𝛼1 + 𝛼2 + 𝛼1𝛼2 + 𝛼3 + 𝛼1𝛼3 + 𝛼2𝛼3 + 𝛼1𝛼2𝛼3 + 𝜀𝑖𝑗 
where 
𝜇𝑖𝑗 = Average Change in Pain (∆𝑃𝑎𝑖𝑛) 
𝛼1 =  {
𝛼𝐸
𝛼𝑂
𝛼𝑅
} = Effect of phase (E, O, or R) on ∆𝑃𝑎𝑖𝑛 
𝛼2 = {
𝛼𝑇
𝛼𝐼
𝛼𝑃
} = Effect of treatment type (TENS, IFC, or placebo) on ∆𝑃𝑎𝑖𝑛 
𝛼3 = {
𝛼𝑃𝐸𝐶𝑂+ 
𝛼𝑃𝐸𝐶𝑂− 
} Effect of ischemia (PECO+ or PECO-) on ∆𝑃𝑎𝑖𝑛 
𝜀𝑖𝑗 = Residuals, or errors around the predicted trendline 
The expanded prediction expression is in Appendix K. 
This model allowed us to test the hypothesis that neurostimulation decreases pain 
perception. However, because the effects of treatment phase and ischemic conditions can 
impact the analgesic effects of TENS and IFC, we evaluated the interactions between 
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treatment type, treatment phase, and ischemia. We also accounted for between-subject 
variability by including subject in the model. 
3.4.3 Change in Vascular Resistance associated with Change in Pain 
The next step was to create a model to examine a possible relationship between 
changes in pain and changes in cutaneous perfusion associated with neurostimulation 
under ischemic and non-ischemic tissue conditions. Similar to the first model, inputs 
included subject, treatment type, ischemia, and phase, with ∆𝑉𝑅̅̅ ̅̅  as the response variable. 
However, this model also included pain measurements as a fixed input. The MPQ pain 
scale was the most successful at detecting changes in pain during exercise and occlusion 
and was therefore used in this model. However, ∆pain during the recovery period is 
assumed to be zero in this model. If the correlation between ∆pain and ∆𝑉𝑅̅̅ ̅̅  during 
recovery is of interest, the NRS or Faces pain scale should be used as the response 
variable. The shorthand prediction expression for the relationship between ∆𝑉𝑅̅̅ ̅̅  and 
∆MPQ pain is: 
log10(VR+10) = ∆𝑉𝑅̅̅ ̅̅ ̅̅  + Phase + Ischemia + Treatment + ∆MPQ + Phase*∆MPQ + 
Ischemia*∆MPQ + Treatment*∆MPQ + Subject 
This expression is written as a general linear model in the form:  
𝑦𝑜 = 𝛽𝑜 + 𝛼1 + 𝛼2 + 𝛼3 + 𝛽1𝑥𝑖 + 𝛽1𝛼1 + 𝛽1𝛼2 + 𝛽1𝛼3 + 𝜀𝑜 
where 
𝛽𝑜 = Average Vascular Resistance (∆𝑉𝑅̅̅ ̅̅ ) 
𝛼1 =  {
𝛼𝐸
𝛼𝑂
𝛼𝑅
} = Effect of phase on ∆𝑉𝑅̅̅ ̅̅  
𝛼2 = {
𝛼𝑇
𝛼𝐼
𝛼𝑃
} = Effect of treatment type on ∆𝑉𝑅̅̅ ̅̅  
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𝛼3 = {
𝛼𝑃𝐸𝐶𝑂+ 
𝛼𝑃𝐸𝐶𝑂− 
} Effect of ischemia on ∆𝑉𝑅̅̅ ̅̅  
𝛽1 = Effect of ∆MPQ pain on ∆𝑉𝑅̅̅ ̅̅ ; slope change 
𝜀𝑜 = Residuals, or errors around the predicted trendline 
The complexity of the model warranted statistical signiﬁcance at p ≤ 0.01. No data points 
were excluded as outliers, and it was reasonable to assume equal variance in the dataset 
(Levene: p > 0.05). The expanded prediction expression is in Appendix L.  
This model allowed us to test the possible correlation between change in vascular 
resistance and change in pain. However, because the effects of treatment phase and 
ischemic conditions have compounding effects on perfusion and pain independent of 
neurostimulation, we evaluated the interactions between TENS/IFC, treatment phase, and 
ischemia. We also accounted for between-subject variability by including subject in the 
model. 
3.5 RESULTS  
 To test the hypothesis that neurostimulation increases perfusion and decreases 
SNS tone (based on reduction in HR), the absolute changes in local BF, contralateral BF, 
HR, MBP, VR, and ischemic pain were divided into phase, treatment type, and ischemic 
condition for analysis, Appendix M and N. Change in vascular resistance and change in 
pain were modeled separately and together in JMP statistical software based on the 
effects of phase (Exercise, Occlusion, Recovery), treatment type (TENS, IFC, Placebo), 
and ischemia (PECO+, PECO-), Appendix O.  
3.5.1 Change in Blood Flow  
 As expected, blood flow in the treatment arm (termed local blood flow) increased 
from resting baseline during exercise due to increased metabolic demand, decreased 
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during occlusion due to manual compression of the arterioles, and increased rapidly 
during the recovery phase due to reactive hyperemia. However, neither neurostimulation 
treatment increased blood flow as compared to placebo treatment, though interestingly 
both TENS and IFC have a general trend towards decreased blood flow in both ischemic 
and non-ischemic conditions, Figure 3.3. During occlusion, TENS and IFC tend to 
exaggerate ischemia, while during recovery, TENS and IFC tend to dampen reactive 
hyperemia. Interestingly, both forms of neurostimulation appear to have a latent 
inhibitory effect on blood flow under non-ischemic conditions after exercise. 
 
Figure 3.3: Effects of Phase, Treatment, and Ischemia on ΔBlood Flow.  A. Local 
blood flow (PU) data trace showing increased blood flow during exercise, reduced flow 
A 
B 
C 
* 
* 
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during occlusion, and reactive hyperemia during recovery. B. Contralateral blood flow 
data trace (PU). Arrows indicate the major drops in perfusion associated with blood 
pressure measurements. C. Change in local blood flow (PU) by phase, treatment type, 
and ischemia. Values are shown as mean ± SE. *p≤0.05 for ∆blood flow vs. ischemia & 
phase.  
 
3.5.2 Change in Vascular Resistance 
∆𝑉𝑅̅̅ ̅̅  is reflective of changes in both blood flow and pressure and therefore gives a 
more complete picture of the effects of neurostimulation on perfusion in ischemic tissues. 
As expected, occlusion increases ∆𝑉𝑅̅̅ ̅̅ , and ∆𝑉𝑅̅̅ ̅̅  decreases during reactive hyperemia 
following occlusion, Figure 3.4. The increase in 𝑉𝑅̅̅ ̅̅  during the exercise phase cannot be 
attributed to the occlusion, indicating that static exercise itself creates ischemic 
conditions.  
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Figure 3.4: Effects of Phase, Treatment, and Ischemia on ∆Vascular Resistance. 
These factors affect the normalized ∆𝑉𝑅̅̅ ̅̅  both directly and indirectly through interactions. 
A. Effect of phase on ∆𝑉𝑅̅̅ ̅̅ . B. Effect of treatment type on ∆𝑉𝑅̅̅ ̅̅ . C. Effect of ischemia on 
∆𝑉𝑅̅̅ ̅̅ . D. Effect of interaction between phase and ischemia on ∆𝑉𝑅̅̅ ̅̅ . E. Effect of 
interaction between phase and treatment on ∆𝑉𝑅̅̅ ̅̅ . F. Effect of interaction between 
treatment and ischemia on ∆𝑉𝑅̅̅ ̅̅ . Values are shown as log10(means) ± SE. *p≤0.05 for 
∆𝑉𝑅̅̅ ̅̅  vs. phase, treatment, & ischemia. 
 
Interestingly, IFC increases ∆𝑉𝑅̅̅ ̅̅  as compared to placebo under acute ischemic 
conditions while there is no effect of TENS on ∆𝑉𝑅̅̅ ̅̅  during occlusion, Figure 3.5. 
Furthermore, the latent effect observed in the blood flow data is reflected in the vascular 
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resistance data. Both TENS and IFC increase ∆𝑉𝑅̅̅ ̅̅  7-9 minutes after static exercise under 
non-ischemic conditions, though during reactive hyperemia this effect is lifted as the 
tissues recover from the acute ischemic event. 
 
Figure 3.5: Mean Changes in Vascular Resistance for TENS, IFC, and Placebo 
Treatments during each Phase and Ischemic Condition. IFC increases ∆𝑉𝑅̅̅ ̅̅  as 
compared to placebo during ischemia, and both TENS and IFC increase ∆𝑉𝑅̅̅ ̅̅  under non-
ischemic conditions versus ischemic conditions during the recovery phase following 
acute ischemia. Values are shown as means ± SE. *p≤0.05 for ∆𝑉𝑅̅̅ ̅̅  vs. phase, treatment, 
& ischemia. 
 
3.5.3 Change in Pain 
 As previously mentioned, three separate scales were used to assess pain and 
paresthesia to discern the effect of neurostimulation on ischemic pain. Pain was assessed 
during the exercise and occlusion phases using the MPQ scale and every minute using the 
---------*--------- 
* 
* 
---------------*--------------- 
---------*--------- 
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NRS and Faces scales. To compare trends from each phase of the treatment, the pain data 
from the NRS and Faces scales were consolidated into the four main phases of the 
protocol and normalized to baseline. All three scales captured ischemic pain associated 
with occlusion, though one of the scales show a difference between TENS, IFC, or 
placebo treatment types in their effect on ischemic pain, Figure 3.6, Appendix O Table 
III.B. The MPQ scale shows the greatest difference in ∆pain during the occlusion phase 
under ischemic versus non-ischemic conditions, while the NRS scale was the least 
effective at showing changes in pain. Pain increases during exercise on the MPQ and 
Faces scales, indicating that exercise induces pain independent of ischemia, Figure 3.7. 
 
 
Figure 3.6: Trends in ∆NRS Pain by Treatment Type, Phase, and Ischemia. NRS 
pain increases during occlusion and remains elevated during recovery for every treatment 
type. When ischemia is induced, NRS pain increases more during occlusion. Values are 
shown as means ± SE. *p ≤ 0.001 for ∆pain vs. phase, treatment, & ischemia. 
 
∆
 
59 
 
 
Figure 3.7: Trends in ∆Pain by Phase and Ischemia. ∆Pain is greatest during the 
occlusion phase with ischemia as shown by the A. MPQ scale, B. NRS, and C. Faces 
scale. The other 2-way interactions for ∆pain between ischemia and phase have different 
trends across the different scales. Values are shown as means ± SE. *p ≤ 0.001 for ∆pain 
vs. phase & ischemia. 
 
While the NRS and Faces scale show no differences in ∆pain within the exercise 
and recovery phases (p ≥ 0.05), there are different trends in directionality between the 
two scales. According to the NRS, pain trends toward a decrease during the exercise 
phase, increases during the occlusion phase, and trends toward an increase in the 
recovery phase. In contrast, the Faces scale trends toward an increase in pain for all three 
phases. The NRS model is only able to explain 33% of the variability in change in 
ischemic pain (R2 = 0.33), indicating that it has little predictive power. The Faces scale is 
able to explain 61% of the variability (R2 = 0.61), and for this reason only the MPQ and 
Faces scales are used for further analysis.  
 
* * * A B C 
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3.5.4 Change in Vascular Resistance associated with Change in Pain 
To test the hypothesis the analgesic effect is dependent upon decreases in vascular 
resistance, the relationship between ∆𝑉𝑅̅̅ ̅̅  and ∆pain is analyzed for each experimental 
phase, treatment type, and ischemic condition, Appendix O, Table 3.C.  
As expected, ischemic conditions during the occlusion phase invoke a strong 
positive relationship between ∆𝑉𝑅̅̅ ̅̅  and ∆pain, Figure 3.8A. However, during the exercise 
phase, there is a slightly negative relationship such that ∆𝑉𝑅̅̅ ̅̅  decreases as ∆pain 
increases. This again suggests an exercise-mediated pain pathway is present and operates 
independently of ischemic pain mechanisms. Interestingly, ∆𝑉𝑅̅̅ ̅̅  trends to increase more 
rapidly in relation to pain with IFC treatment as compared to TENS and placebo, though 
there are no significant differences in the relationship between ∆𝑉𝑅̅̅ ̅̅  and ∆pain between 
the three treatment types, Figure 3.8B. 
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Figure 3.8: Effects of Ischemia, Phase, and Treatment Type on the Relationship 
between ∆MPQ Pain and ∆𝑉𝑅̅̅ ̅̅ . Ischemia and pain influence the relationship between 
∆pain and ∆𝑉𝑅̅̅ ̅̅ . A. ∆MPQ Pain and Ischemia. B. ∆MPQ Pain and Treatment. 
 
3.6 DISCUSSION 
The main goal of this study was to investigate trends in increased blood flow and 
decreased vascular resistance and pain associated with neurostimulation under ischemic 
conditions, possibly due to a decrease in sympathetic tone and increase in C fiber 
inhibition mediated by Aβ fiber activation. We could not detect any significant 
A 
∆ 
B 
∆ 
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hyperemic or analgesic effects of either TENS or IFC as predicted, though interestingly 
neurostimulation tended to increase vascular resistance during acute ischemia as well as 
under non-ischemic conditions after static exercise.  
 In a similar study in healthy young subjects similar to our study population, TENS 
increased blood flow and lowered vascular resistance in the calf [32]. The discrepancy 
between the results of the two studies is most likely not due to statistical power; our study 
had 45 replicates while the comparator study had 12. Rather, the different results may be 
due to differences in blood flow measurement techniques, with calf blood flow measured 
using venous occlusion plethysmography (VOP) as compared to cutaneous palmar blood 
flow measured using laser Doppler flowmetry (LDF) in our study. Plethysmography is a 
volume-based measurement, while laser Doppler signals are recorded in arbitrary 
Perfusion Units (PU) based on a motility standard that does not take tissue volume into 
account [75]. Thus, VOP may capture whole limb blood flow while LDF is limited to 
cutaneous perfusion. 
 Indeed, the relationship between LDF and VOP blood flow measurements during 
exercise is nonlinear [76]. LDF and VOP measurements are similar during early 
cutaneous vasodilation, but in later phases LDF values level off while VOP perfusion 
measurements increase. Furthermore, differences tissue composition between subjects 
can affect blood refractivity, introducing inter-subject type II error in LDF measurements 
[77], and therefore between-subject variability must be controlled for by including 
subject in the data analysis. Although measurements taken from both techniques reflect 
changes in perfusion, the magnitudes of changes in blood flow during active vasodilation 
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would not correlate. Thus, it is possible that neurostimulation had a greater hyperemic 
effect than measured.  
 We hypothesized that neurostimulation inhibits sympathetic vasoconstriction by 
inhibiting NE release at peripheral sympathetic nerve terminals. Therefore, 
neurostimulation ought to affect whole-limb blood flow, not just cutaneous blood flow. 
To more accurately assess whole-limb hemodynamic responses, future researchers should 
consider using an alternative system such as VOP to measure tissue perfusion rather than 
LDF. However, since VOP is too invasive to be feasible for use at Cal Poly, ultrasonic 
blood flow monitoring may serve as an effective alternative. Ultrasound techniques are 
used to detect early stages of atherosclerosis in peripheral arteries by measuring real-time 
blood velocities [78]. Similarly to LDF, ultrasound blood flow profiles will decrease 
during occlusion and can be used to screen for ischemic conditions. However, ultrasound 
blood flow measurements are more accurate than those taken with LDF systems [79]. 
Hand-held ultrasound blood flow measurement systems are affordable within the Cal 
Poly MEDITEC budget and are feasible for student use [80]. 
 Since our blood flow measurement system may have been limited to cutaneous 
blood flow, neurostimulation may have a more profound effect on vascular tone 
throughout the forearm tissue than captured by our measurements. However, trends in 
vascular resistance and pain were observed with neurostimulation in response to 
ischemia, Table 3.2. 
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Table 3.2: Experimental Trends in Hemodynamic Factors and Pain during 
Recovery.  
Expected Outcome 
Placebo TENS IFC 
PECO- PECO+ PECO- PECO+ PECO- PECO+ 
Heart Rate ↓ - ↓ - - ↓ 
Skin Temperature ↑ ↑ ↑ ↑ ↑ ↑ 
Mean Blood Pressure - ↓ ↓ ↓ ↓ ↓ 
Local Blood Flow ↑ ↑↑ ↑ ↑↑ ↑ ↑↑ 
Contralateral Blood Flow ↑ ↑ ↑ ↑ ↑ ↑ 
Vascular Resistance ↓ ↓ - ↓ - ↓ 
Ischemic Pain ↑ ↑ - ↑ - ↑ 
 
3.6.1 Change in Blood Flow 
As expected, local tissues experienced a rapid increase in blood flow following 
occlusion due to the local release of vasodilator metabolites during ischemia. This 
phenomenon, known as reactive hyperemia, was observed for all three treatment types 
during the recovery phase. In addition, blood flow increased during exercise as expected, 
Figure 3.3. Compression of intramuscular arterioles during exercise results in the release 
of endothelial-derived vasodilator metabolites that competitively inhibit the effects of NE 
and thus inhibit sympathetic vasoconstriction in active tissues [81]. Forearm blood flow 
is higher at 30% than at 10% maximum voluntary contraction in the forearm following a 
2 minute isometric contraction [82], indicating that SNS activity can be prevented by 
low-intensity exercise. These results followed the same general trends across all groups, 
Appendix N, with very little between-subject variability, Appendix P. 
We hypothesized that an additional vasodilatory mechanism independent of 
reactive hyperemia and functional sympatholysis would be present in vessels undergoing 
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neurostimulation. Transcutaneous neurostimulation may activate peripheral α-2 
adrenergic receptors [73], inhibiting norepinephrine release and decreasing local 
sympathetic tone. However, neurostimulation did not have its expected effect. Both 
TENS and IFC had a general trend towards decreased blood flow in both ischemic and 
non-ischemic conditions such that ischemia was more severe during occlusion while 
reactive hyperemia was dampened. 
It is possible that we did not see an increase in blood flow associated with 
neurostimulation if there was no electrical α-2 adrenergic activation during exercise or if 
metabolic vasodilation during exercise amplified the hyperemic response and 
overwhelmed any additional increase in blood flow caused by electrical α-2 adrenergic 
activation. In order to distinguish between these two possibilities, we must include a non-
exercise group in future studies and compare changes in blood flow with and without 
neurostimulation between the exercise and non-exercise groups. 
            Although a statistically significant difference eluded our study, the application of 
TENS and IFC to the ganglions can increase peripheral vasodilatory capacity and reduce 
blood pressure at the end of exercise in young healthy subjects [39, 32, 52], though there 
are conflicting reports on their efficacy. The mechanisms behind these observed 
hemodynamic trends is still unclear, though the blood flow measurement methods of 
VOP and ultrasound, respectively, may have introduced inconsistencies when comparing 
studies. 
As stated previously, it is possible that the changes in cutaneous blood flow 
observed using LDF were not reflective of changes in whole-limb perfusion associated 
with neurostimulation. It is also possible that the increase in local blood flow regardless 
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of treatment type may be linked to metabolic vasodilator substances released during the 
isometric handgrip exercise. To isolate the effects of exercise from occlusion and 
neurostimulation on hyperemia, future studies ought to have both an exercise group and a 
non-exercise group in addition to blocking by treatment type (TENS, IFC, and placebo). 
If blood flow is reduced in non-exercise groups as compared to exercise groups, then 
exercise-induced vasodilation would indeed be a compounding effect. 
 However, this explanation for the negative blood flow results cannot account for 
the latency of the inhibitory effect of neurostimulation on exercise hyperemia when the 
occlusion was not applied. Previous evidence suggests that pre-treatment with TENS has 
no immediate effect on local blood flow but improves exercise tolerance at later time 
points [48]. Although the mechanism is unclear, it is possible that latent effects of both 
TENS and IFC may be associated with latencies in cellular activation. Transcutaneous 
stimuli have to travel through layers of skeletal muscle and connective tissue before they 
reach sympathetic neuron cell bodies in the ganglion, and signal impedance may be a 
time-dependent function of tissue conductance [83]. Therefore, it is possible that the 
stimuli did not sufficiently activate SNS neurons until later time points. Future studies 
may consider including a 5 minute pre-conditioning phase before beginning the trial in 
order to allow for the stimuli to overcome surface impedance and penetrate the ganglion. 
3.6.2 Change in Vascular Resistance 
 The trends observed in the blood flow responses are reflected in the vascular 
resistance responses. Occlusion increases ∆𝑉𝑅̅̅ ̅̅  as expected, though interestingly IFC 
increases ∆𝑉𝑅̅̅ ̅̅  during recovery while TENS tends to increase ∆𝑉𝑅̅̅ ̅̅  as well, Table 3.5. 
Although these results are opposite to our original hypothesis that neurostimulation 
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increases blood flow and decreases ∆𝑉𝑅̅̅ ̅̅ , it does suggest that the hemodynamic effects of 
IFC may be more exaggerated than those of TENS as we predicted. Furthermore, both 
TENS and IFC increase ∆𝑉𝑅̅̅ ̅̅  under non-ischemic conditions after static exercise, though 
during recovery this effect is diminished as reactive hyperemia takes over following the 
acute ischemic event. However, the effect of occlusion on ∆𝑉𝑅̅̅ ̅̅  is so much greater in 
magnitude than the effect of TENS or IFC that changes in ∆𝑉𝑅̅̅ ̅̅  associated with either 
form of neurostimulation could be considered clinically insignificant. 
 One possible explanation for why we did not see a decrease in ∆𝑉𝑅̅̅ ̅̅  associated 
with neurostimulation during acute ischemia as predicted is that peripheral α-2 adrenergic 
activation via electrical stimulation is affected by hypoxic conditions. As previously 
mentioned, electrical stimulation activates α-2 adrenoceptors, disrupting N-type calcium 
current in sympathetic nerve terminals and inhibiting the release of norepinephrine, a 
known vasoconstrictor. However, without sufficient blood flow, normal functioning of α-
2A receptors may be disrupted. For example, forebrain ischemia decreases α -2A receptor 
binding in the rat hippocampus [84]. A similar event may be occurring in α-2A receptors 
at the ganglion or at the synapse with smooth muscle cells following peripheral occlusion 
in healthy young humans, though the mechanism is not clear. 
 Although we postulated that electrical stimuli have an inhibitory effect on 
sympathetic signal transmission in Aβ fibers, a second possible explanation for the 
observed inhibition of vasodilation associated with neurostimulation is that TENS and 
IFC actually activated peripheral SNS neurons. To our knowledge there are no 
comparative studies with published data indicating increased sympathetic vascular tone 
associated with ganglial stimulation; however, TENS treatment has been used to activate 
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the sympathetics in healthy humans [85], and since the somas of efferent SNS neurons 
are located in the same ganglia as the somas of efferent Aβ fibers, it is possible that 
transcutaneous stimulation applied at the ganglia activated efferent vascular SNS fibers 
as opposed to efferent Aβ fibers and ultimately increased peripheral sympathetic 
vasoconstriction.  
3.6.3 Change in Pain 
 Pain is present throughout the experimental protocol regardless of phase, ischemic 
conditions, or the type of neurostimulation applied, Figure 3.6. The MPQ scale 
quantified the greatest magnitude of ∆pain during the exercise and occlusion periods, and 
the Faces scale corroborates a positive ∆pain during exercise and occlusion as well as 
during the recovery period, Figure 3.7. These results were the same across TENS, IFC, 
and placebo treatments both with and without PECO and therefore do not support our 
hypothesis that transcutaneous neurostimulation decreases ischemic pain.  
 There is a general consensus that neurostimulation, including TENS and IFC, 
attenuates both chronic and acute ischemic pain [32, 62, 64, 66, 37]. However, the onset 
and duration of analgesia may vary considerably between patients [37], and the same 
protocol may have different degrees of antinociception in acute experimental pain 
compared with chronic clinical pain [38]. There is also conflicting evidence indicating 
that neurostimulation does not have a significant analgesic effect on this type of pain. IFC 
and TENS treatments have shown no differences in analgesia as compared to 
placebo during ischemic-induced pain tests utilizing the submaximal tourniquet technique 
(similar to our study) and the cold pressor technique. Furthermore, 50 Hz and 100 Hz 
TENS treatments have shown no differences in analgesia as compared to IFC treatments 
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at the same frequency [49, 68, 65, 86]. Therefore the results from our study may be a true 
negative, as opposed to a false negative, and similarly substantiate the observed non-
significance of transcutaneous neurostimulation on acute experimental pain. 
 One possible explanation for the inability of subjects to detect a cessation in pain 
is that that cytokines accumulated during the static handgrip exercise and caused pain. 
While our study was not the first to involve exercise, more than half of our subjects 
gripped above 30% maximal volumetric contraction and did not adequately decrease their 
grip strength when instructed. Therefore, it is possible that our subjects experienced 
greater microdamage to their skeletal muscle tissues and had higher concentrations of 
algesic cytokines, including arachidonic acid (AA). AA is metabolized into 
prostaglandin, which inhibits potassium efflux from nociceptors via a G protein, protein 
kinase A cascade. The sensitized peripheral nociceptors transmit afferent signals to the 
CNS which are interpreted as pain [87]. Although participants only applied 30% of their 
maximum handgrip force, the exercise intensity and duration was sufficient to introduce 
microdamage to the tissues [81, 82]. Analgesic cytokines from the exercise phase may 
have remained un-metabolized in the tissues long enough to induce pain during the 
occlusion and recovery phases as well. Therefore, dynamic exercise may be preferable to 
static exercise for the purpose of our study in order to decrease the buildup of metabolic 
byproducts. 
 It is also possible that summation of afferent exercise and ischemic pain signals 
caused an overall increase in pain. Gate Control Theory postulates that TENS attenuates 
nociception by stimulating Aβ fibers parallel to C fibers responsible for transmitting pain 
signals to the brain [41]. However, the Central Summation Theory proposes that 
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summation of pain may overwhelm the integration center in the thalamus, resulting in 
increased pain [88]. Therefore, the summation of ischemic and exercise-induced pain 
may cause an overall increased pain sensation regardless of Aβ fiber activation via 
neurostimulation. Similar to isolating exercised-induced hyperemic effects, incorporating 
a non-exercise group in future studies would help isolate the effect of exercise from 
occlusion and neurostimulation on pain. If pain is reduced in non-exercise groups as 
compared to exercise groups, then exercise-induced pain would indeed be a compounding 
effect.  
3.6.4 Change in Vascular Resistance associated with Change in Pain 
 We hypothesized that electrical activation of Aβ fibers would reduce 𝑉𝑅̅̅ ̅̅  and pain 
via parallel mechanisms. As expected, painful ischemic conditions during the occlusion 
phase invoke a strong positive relationship between ∆𝑉𝑅̅̅ ̅̅  and ∆pain, Figure 3.8A. 
Graded increases in ischemic pain are associated with graded elevations in 
forearm vascular resistance [89]. This coordination suggests that changes in pain and 
vascular tone may be mechanistically linked, possibly due to a stress response. When the 
brain detects a painful stimulus, the hypothalamus signals the adrenal glands to release 
vasoconstrictive signaling molecules such as adrenaline and NE as part of the “flight or 
fight” response. We see evidence of this phenomenon in how HR tended to decrease over 
the course of each experimental trial, Appendix M, Figure III.C. Therefore we would 
expect that vascular resistance would increase in response to an increase in pain. 
Interestingly, while there are no significant differences in the relationship between 
∆𝑉𝑅̅̅ ̅̅  and ∆pain between the three treatment types, ∆𝑉𝑅̅̅ ̅̅  trends to increase more rapidly in 
relation to pain with IFC treatment as compared to TENS and placebo, Figure 3.8B. This 
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indicates that subjects receiving IFC treatment experience increased vascular resistance in 
response to a painful stimulus. To our knowledge, there is no evidence to date that TENS 
and IFC have a different effect on the relationship between pain and 𝑉𝑅̅̅ ̅̅ , though the 
differences in the trends observed in our study warrant further investigation with a larger 
sample size. We predicted that our clinical study only needed 45 subjects per treatment 
group to see a 10% decrease in VR and pain associated with neurostimulation, assuming 
that the ΔVR and Δpain values observed for the placebo, PECO- group in pilot study IV 
were valid control measurements. However, it is possible that the true between-subject 
and within-subject variability associated with our study design are higher than were 
sampled from pilot study IV, as the student volunteers during the pilot study were 
homogenous in their age, ethnicity, and physical fitness levels. Therefore, increasing our 
sample size to 100 subjects would double the predictive power of this study and may 
increase our ability to observe changes in VR and pain associated with neurostimulation.   
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CHAPTER 4: SUMMARY 
 
4.1 SYNOPSIS 
Peripheral arterial occlusive disease (PAOD) is a pervasive disease characterized 
by impaired metabolic vasodilation in the peripheries. While intermittent claudication 
symptoms develop in symptomatic patients, limb ischemia develops in all cases as the 
disease progresses. The current gold standard of treatment is a combined drug and 
surgical intervention involving statins, antihypertensive drugs, angioplasty, and stenting. 
While this approach addresses the impaired blood flow and pain symptoms associated 
with PAOD, there are often adverse side effects and restenosis.  
Neurostimulation may provide a much-needed innovative treatment option for 
PAOD, as it has a known analgesic effect on both acute and chronic pain and may also 
increase blood flow. Electrical activation of afferent Aβ fibers, either in the periphery or 
near the ganglia, inhibits both pain-signal transmission from afferent C fibers and 
norepinephrine release at sympathetic nerve terminals. The Gate Control Theory explains 
how Aβ fibers activate an inhibitory interneuron in the dorsal horn of the spinal cord that 
synapses with ascending spinothalamic (ST) neurons, effectively dampening the pain 
signal to the brain. Simultaneously, suppression of the ST neurons may result in 
decreased metaboreflex control as systemic sympathetic vasoconstriction is reduced and 
mean blood pressure decreases. Aβ fiber activation is also thought to activate α-2 
adrenoceptors on primary afferent neurons along the same dermatome, resulting in 
suppressed sympathetic tone and an increase in local blood flow. Ultimately, electrical 
stimulation may decrease local vascular resistance (VR), Figure 1.7. 
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 The focus of our study was to optimize methods and perform a small-scale 
clinical study for investigation of hemodynamic and pain responses to neurostimulation 
during an ischemic event in otherwise healthy subjects. We hypothesized that 
transcutaneous electrical neurostimulation (TENS) and interferential current (IFC) 
treatments applied at the C7 and T4 ganglia would result in decreased pain and local 
vascular resistance in the palms and that IFC may have a greater analgesic and hyperemic 
effect than TENS due to differences in stimulus current waveforms. 
Unfortunately, our findings did not directly support either hypothesis. We found 
no significant analgesic or hyperemic effects during or following acute ischemia; rather, 
we saw trends indicating that TENS and IFC increase pain and VR under both ischemic 
and non-ischemic conditions. Interestingly, IFC increased VR under acute ischemic 
conditions while TENS had a lesser effect. We also observed a greater increase in VR 
correlated with an increase in pain with IFC as compared to TENS, indicating that the 
out-of-phase sinusoidal waveform characteristic of IFC may more readily overcome skin 
impedance and have a greater effect on sympathetic tone as predicted.  
4.2 FUTURE WORK 
 Considering the outcome of this study, we would propose several changes to the 
study design that may help to establish clearer conclusions from the data. Future 
researchers should consider replacing the laser Doppler flowmetry blood flow 
measurement system with an ultrasound system as it is both feasible for use by students 
and more accurate at measuring whole-limb perfusion [79]. It would also be 
advantageous to recruit study participants from a more diverse age range (18-25 years 
versus 50+ years) and lifestyle (athletic versus sedentary) by targeting recruitment to 
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professors and student athletes in addition to the general student population, as a healthy 
young sample population is not reflective of the general PAOD patient population [3].  
 Many participants were anxious about using neurostimulation for the first time, as 
evidenced by a general trend towards decreased heart rate over the course of the session, 
Appendix M, Figure III.C. Incorporating an introductory trial run with each participant 
a day or more prior to the study sessions may allow for less stress-induced sympathetic 
response during the data collection. Furthermore, including a non-exercise group will be 
necessary to isolate the effects of exercise from occlusion and neurostimulation on 
hyperemic and analgesic trends. 
 It may also be interesting to further investigate the effects of paresthesia on trends 
in hyperemia and analgesia. Paresthesia introduced significant variability to the pain data 
as it was often perceived by the participants as an unusual or irritating sensation during 
testing, Appendix P. If the stimulus intensity was set to a subparesthesia level, 
sympathetic vasoconstriction due to the stress response and non-painful stimuli 
incorporated into the self-reported pain scores may diminish, possibly resulting in less 
noise in the blood flow and pain data and more pronounced hyperemia and analgesia 
associated with neurostimulation. Furthermore, amplifying the baseline pain signal may 
also improve the signal-to-noise ratio. While the Cal Poly Human Subjects Committee 
approval only extends to 180 mmHg of pressure on the forearm for the submaximal 
tourniquet technique, it is possible that moving the site of occlusion to the upper arm may 
be more painful for most people than an equivalent pressure on the forearm. Interestingly, 
the amount of pain induced by the submaximal tourniquet technique in our study was less 
than that captured in comparator studies using a similar numeric rating scale; therefore, 
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an alternative ischemic pain method should be considered. The cold pressor test may also 
be used to test the analgesic and hyperemic effects of neurostimulation and may provide a 
greater painful stimulus that the tourniquet technique [65, 68].  
 Finally, incorporating a measurable control for skin surface electrode impedance 
may be important for standardizing treatment across subjects. While future studies ought 
to consider including a 5 minute pre-conditioning phase in order to control for the latent 
effects of transcutaneous stimulation and allow time for the stimuli to overcome surface 
impedance, slight differences in electrode configuration and tissue conductance between 
patients can alter the electric field distribution and thereby the depth and selectivity of 
neural activation [83]. Although we attempted to control the shape and depth of the 
electric field by standardizing electrode placement, a more accurate approach may be to 
use a multimeter to quantitatively assess surface impedance. While most 
electromyography (EMG) units have a built-in impedance sensor to direct electrode 
placement, commercially available TENS units do not [90]. Incorporating a similar user 
feedback mechanism into future TENS unit designs would be desirable. 
Although our study was not able to find significant evidence that IFC has a 
greater analgesic or hyperemic effects than TENS, nor that transcutaneous 
neurostimulation in general had such effects, further characterization of the different 
stimulus waveforms may provide great insight into extracellular electrical control of 
vascular tone. 
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APPENDICES 
 
Appendix A: Informed Consent Form 
 
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH PROJECT:  
“The Effects of Transcutaneous Electrical Neurostimulation on Analgesia and 
Peripheral Perfusion” 
A research project on peripheral blood flow and ischemic pain is being conducted 
by Leah Schafer and Kaylee Keck in the Department of Biomedical Engineering at Cal 
Poly, San Luis Obispo. The purpose of the study is to measure changes in blood flow, 
heart rate, and blood pressure due to the application of electrical neurostimulation. 
You are being asked to take part in this study by first filling out a short medical 
history questionnaire. Questions marked with an asterisk (*) are required, but any others 
you do not wish to answer may be omitted. These questions are directly related to your 
safety. During each treatment session, you will be hooked up to a neurostimulation 
device that will be attached to your upper back with electrodes, a blood flow 
measurement system using skin probes on the upper arms, a respiration belt wrapped 
around your midsection, and a blood pressure cuff applied to each arm. Appropriate 
clothing should be worn to ensure proper placement of the electrodes on your upper back. 
Prior to the treatment session, you will be asked to not consume caffeine for up to 12 
hours before the session in an effort to minimize caffeine’s effects on blood flow. Once 
the session begins, you will be asked to squeeze a handgrip force measurement device for 
a short period of time. You will experience electrical stimulation from the attached 
electrodes, which you may feel as a warm, tingling sensation on your back. Your 
participation will involve 6 sessions, with a 10-minute break (5 breaks) in between each 
session, for a total of 2 hours on one day. In some of these sessions, the neurostimulation 
device will be hooked up to you, but no current will be applied, as in you will not feel 
any sensation on your back. This will be randomized. Please be aware that you are not 
required to participate in this research and you may discontinue your participation at any 
time without penalty.  
The possible risks associated with participation in this study include pain due to 
temporarily induced ischemia i.e. insufficient blood flow to the tissue, skin irritation from 
the application of skin probes and electrodes, and possible discomfort and/or stress from 
gripping the hand force measurement device. If your personal pain tolerance threshold is 
reached at any point, you may discontinue your participation immediately. If you should 
experience residual pain or tingling after the duration of the experiment or an allergic 
reaction at the site of the probes or electrodes, please be aware that you may contact Cal 
Poly Health and Counseling Services, located in building 27, at (805) 756-1211 for 
assistance. 
Your confidentiality will be protected by recording your medical history, age, 
gender, height and weight on a document with a corresponding code. This document will 
be kept as a hard copy only and separate from the corresponding list of codes. Your 
information will only be accessible to the researchers in this study. If the results of the 
study are published, any identifying information will be omitted. The incentive associated 
with this study is a benefit in the form of a $25 Visa gift card to those that choose to 
85 
 
participate and agree to the caffeine restrictions. In the case that you choose to 
prematurely discontinue your participation due to possible discomfort and/or stress, 
monetary compensation will still be provided. You may only volunteer once for this 
study. Depending on the outcome of the study, this could become an additional treatment 
method for individuals with ischemic pain. 
If you have questions regarding this study or would like to be informed of the 
results when the study is completed, please feel free to contact Leah Schafer at (530) 354-
5061 or Dr. Trevor Cardinal at (805) 756-6244. If you have concerns regarding the 
manner in which the study is conducted, you may contact Dr. Steve Davis, Chair of the 
Cal Poly Human Subjects Committee, at (805) 756-2754, sdavis@calpoly.edu, or Dr. 
Dean Wendt, Dean of Research, at (805) 756-1508, dwendt@calpoly.edu. 
If you agree to voluntarily participate in this research project as described, please 
indicate your agreement by signing below. Please keep one copy of this form for your 
reference, and thank you for your participation in this research. 
 
 
______________________________________________________________ 
Signature of Volunteer                                                                  Date 
 
 
______________________________________________________________ 
Signature of Researcher                                                                Date 
  
86 
 
Appendix B: Medical History Questionnaire 
 
MEDICAL HISTORY 
*= Required 
General Information 
Participant: 
*Name:___________________________________________________________ 
*Email: __________________________ Contact phone number: _____________ 
*Dominant Hand:  □ Right □ Left 
Age: _________________________________ 
Height: _______________________________ 
Weight: _______________________________ 
 
Sex: 
□ Male □ Female 
Women only answer the following: 
*Are you currently pregnant?          □ Yes □ No 
Are you currently breast-feeding?   □ Yes □ No 
 
Men and women answer the following: 
*Have you consumed caffeine in the last 12 hours?  □ Yes □ No 
*Have you exercised to at least 50% of your maximum heart rate (moderate 
exercise) in the last: 
 48 hours?  □ Yes  □ No 
 12 hours?  □ Yes  □ No 
List any prescription medications you are currently taking:  
__________________________________________________________________ 
Do you have any implantable electrical devices (pacemaker, implantable 
cardioverter defibrillator, etc.)?       
  □ Yes     □ No       If yes, please list: ________________________________ 
In the past two months, have you experienced any major injury or significant 
trauma to your arms or upper back?        □ Yes     □ No       If yes, please 
describe:  _________________________________________________________ 
[over] 
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Past Medical History 
 
Have you experienced any of the following: 
Yes No 
 □ □   *Dermatitis/eczema (inflammation of the skin) 
 □  □   *Chronic pain or tingling sensations in your limbs 
 □  □   *Syncope (fainting) 
 □  □   *Epilepsy or seizures 
 □  □   Heart attack 
 □ □   High blood pressure (hypertension) 
 □ □   Rheumatic Fever 
 □ □   Heart murmur (abnormal heart sound) 
 □ □   Arrhythmia (irregular heartbeat) 
 □ □   Diseases of the arteries (peripheral artery disease, coronary artery disease) 
 □ □   Varicose veins (twisted, enlarged veins) 
 □ □   Diabetes or abnormal blood sugar 
 □ □   Phlebitis (inflammation of the veins) 
 □ □   Stroke 
 □ □   Anemia (low red blood cell count) 
 
Smoking 
Have you ever smoked tobacco?         □ Yes □ No 
If yes, how long did you smoke/how long have you been smoking?__________ 
How frequently did/do you smoke? ___________________________ 
Drinking 
On average, do you drink more than 1 alcoholic beverage per day (women)/ 2 
alcoholic beverages per day (men)?         □ Yes        □ No 
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Appendix C: W9 Tax Form  
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Appendix D: Cal Poly Human Subjects Committee Approval Form  
 
All Cal Poly faculty, staff, and student research with human subjects, as well as other research 
involving human subjects that is conducted at Cal Poly, must be reviewed by the Cal Poly 
Human Subjects Committee for the protection of human subjects, the researchers, and the 
University. Human subjects research is defined as any systematic investigation of living human 
subjects that is designed to develop or contribute to generalizable knowledge. While the ethical 
guidelines for research are applicable to classroom activities, demonstrations, and assignments, 
the Human Subjects Committee does not review classroom activities unless data will be collected 
and used in a systematic investigation.  
 
Researchers should complete all items on this approval form and submit it, along with a research 
protocol (containing the information detailed in Guidelines for Human Subjects Research 
Protocol), to the Office of Research and Economic Development (Debbie Hart, Bldg. 38, Room 
154). Please feel free to attach an additional page if your responses to any of the items require 
more space. Your answers to the items on this form, as well as the research protocol, should be 
typed. The Committee will make every effort to respond to your submission within two to four 
weeks. Committee approval should be received prior to contacting prospective subjects and 
collecting data. Please read carefully Cal Poly's Policy for the Use of Human Subjects in 
Research prior to completing this application.   
If you require assistance in completing this form,  
contact the Office of Research and Economic Development at (805) 756-1508. 
 
1.  Date: 4/12/15 3.  Type of Research: 
  x Senior project 
2.  Title of Research Project:  x Master’s thesis 
 The Effects of Transcutaneous Electrical 
Neurostimulation on Analgesia and Peripheral 
Perfusion 
  Faculty research 
  Other:  
  please explain 
 
 
4.  Name(s) of Researcher(s) 
 Principal Investigator: Leah Schafer 
 Department or other affiliation: Biomedical Engineering 
 Phone: 5303545061 Email: lischafe@calpoly.edu 
 Position:  Faculty x Student 
  Other:  please explain 
 Additional Researcher: Kaylee Keck 
 Department or other affiliation: Biomedical Engineering 
 Phone: 5599205233 Email: kkeck@calpoly.edu 
 Position:  Faculty x Student 
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  Other: please explain 
 Additional Researcher:  
 Department or other affiliation:  
 Phone:  Email:  
 Position:  Faculty  Student 
  Other: please explain 
Any additional researchers involved in the project should be listed with the descriptive 
information requested above on a separate sheet. 
 
5.  Faculty Advisor (if applicable) 
 Name: Trevor Cardinal, Ph.D. Email: tcardina@calpoly.edu 
 Department or other affiliation: Biomedical Engineering Phone: 8057566244 
Other thesis committee members if the research is a thesis: 
 Name: Stuart Rosenberg Email: srosenberg@sjm.com 
 Department or other affiliation: St. Jude Medical Phone: 8184933629 
 Name: Melanie Goodman, Ph.D. Email: mgoodman2@sjm.co 
 Department or other affiliation: St. Jude Medical Phone: 9725264683 
 Name: Kristen O’Halloran Cardinal, Ph.D. Email: kohallor@calpoly.edu 
 Department or other affiliation: Biomedical Engineering Phone: 8057562675 
 
6.  Is there an external funding source for the project: 
x Yes, and the source is: St. Jude Medical MEDITEC 
 No 
 
7.  Is this a modification of a project previously reviewed by Cal Poly’s Human Subjects 
Committee? 
x Yes, and the approximate date of the last review was: 2/11/15 
 No 
 
8.  Estimated duration of the project: 
 Starting date: 5/1/15 Completion date: 7/1/15 
 
9.  Describe any risks (physical, psychological, social, or economic) that may be involved.  
See Specific Ethical Criterion #1 in Policy for the Use of Human Subjects in Research for a description of the 
types of risks. 
The participant will experience ischemic pain i.e. pain resulting from insufficient blood flow 
to a tissue as a result of acute forearm occlusion by a sphygmomanometer at 180 mmHg for 3 
minutes. The participant may experience slight skin irritation with the application of skin 
probes and electrodes. The participant may experience some discomfort during static 
handgrip exercise for 3 minutes. 
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10.  Indicate what measures will be taken to minimize risks. See Specific Ethical Criterion #1 in 
Policy for the Use of Human Subjects in Research for a discussion of strategies for minimizing risks. 
The temporarily induced ischemic pain will be assessed every minute using Numeric Rating 
and Faces pain scales similarly to related published research methodologies. Ischemia will not 
be held for over 3 minutes at 180 mmHg in accordance with clinical instructions for use. If 
pain intensity reaches a subject’s personal pain tolerance threshold, the trial will be 
immediately terminated. For skin irritation k a topical antihistamine (Benadryl) may be 
applied to the area. Handgrip exercise will not exceed 3 minutes. 
 
11.  Explain how subjects' confidentiality will be protected. See Specific Ethical Criterion #5 in 
Policy for the Use of Human Subjects in Research for a discussion of strategies for minimizing risks. 
Participant information will be recorded in terms of their medical history, age, gender, height, 
and weight. This information will be recorded in a hard copy of the medical questionnaire 
document with a corresponding code for each patient. These documents will be kept in Dr. 
Trevor Cardinal’s locked office or in a locked drawer in the testing lab. All data recordings 
will be stored electronically on the P.I.’s personal computer and accessible only to Leah 
Schafer, Kaylee Keck, and Dr. Cardinal. 
 
12.  Describe any incentives for participation that will be used. See Specific Ethical Criterion #2 
in Policy for the Use of Human Subjects in Research for a discussion of the use of incentives in research. 
A $25 Visa gift card will be offered to participants that agree to the caffeine restrictions. In the 
case that a participant chooses to prematurely discontinue their participation due to possible 
discomfort and/or stress, monetary compensation will still be provided. 
 
13.  Will deception of subjects be involved in the research procedures? 
x Yes*  No 
*If so, explain the deception and how it will be handled. See Specific Ethical Criterion #3 in 
Policy for the Use of Human Subjects in Research for a discussion of the use of deception in research: 
The study is designed to be single-blinded such that the participant does not know whether 
they are in a placebo (control) trial or treatment trial. The control trial will involve attaching 
neurostimulation electrodes just as in the treatment trial; however, no electrical stimulation 
will occur during control. This is necessary to determine if the neurostimulation itself is 
actually causing the changes witnessed. 
 
 
14.  Type of review requested: 
  Exempt from further review* x Expedited review  Full review 
See Types of Review in Policy for the Use of Human Subjects in Research for a discussion of 
the criteria for exempt, expedited, and full reviews.  
*The research protocol submitted for a project presumed to be exempt may be abbreviated but should contain 
sufficient information to support the conclusion that the project meets the criteria for exemption. 
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Appendix E: Pilot Study Experimental Design Summary Presentation 
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Appendix F: Protocol  
 
I. Setup  
1. Turn on the laptop. 
2. Connect the power supply to PowerLab.   
3. Connect the USB cable from PowerLab to the laptop.   
4. Connect the respiration belt to Input 1 on the front panel of PowerLab.  
5. Connect the Hand Dynamometer to Input 2 on the front panel of PowerLab.   
6. Connect the power supply to the Laser Doppler Flow (LDF) system and turn it 
on.   
7. Connect the skin probes to Channels 1 and 2 on the LDF system.  
8. Connect the BNC cables from the LDF system to Inputs 3 and 4 on the front 
panel of PowerLab.   
9. Turn on the PowerLab system.  
10. Open LabChart on the laptop and open the customized settings file.  
i. The raw breath signal in millivolts (mV), the respiratory rate in breaths 
per minute (BPM), the handgrip force in Newtons (N), CBF 1 in 
perfusion units (PU), and CBF 2 in PU should all be displayed in 
LabChart at this point.   
II. Application  
1. Seat the participant in a chair with both arms supinated and gently resting on the 
tray. Ensure that they are comfortable and properly positioned before continuing.   
2. Apply the electrodes to the C7 and T4 vertebrae locations, approximately 3 cm to 
the left and right of the vertebral column (Figure 1).†  
3. Wrap the respiration belt around the participant’s chest, just below the xiphoid 
process.  
4. Attach the skin probe connected to Channel 1 of the LDF system to the left arm, 
2 cm below the crease of the wrist.   
5. Attach the skin probe connected to Channel 2 of the LDF system to the right arm, 
2 cm below the crease of the wrist.   
6. Wrap the cuff connected to the manual sphygmomanometer around the 
participant’s left forearm, 2 cm below the crease of the elbow.  
7. Wrap the cuff connected to the blood pressure monitor around the participant’s 
right arm. 
8. Instruct the participant to loosely grip the Hand Dynamometer in their dominant 
hand.   
9. Instruct the participant to squeeze the Hand Dynamometer as hard as possible for 
a second or two, and then relax their grip.*  
10. Determine Maximum Voluntary Contraction (MVC) by recording the average of 
three handgrip trials and calculate 25% of MVC. 
 
* Adapted from BMED 460 – “Muscle Stimulation Fatigue Student Protocol” by Trevor Cardinal 
† Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects." by 
Vieira, et. al. 
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Figure 1: TENS Electrode Placement at the C7 and T4 Regions* 
III. Treatment  
1. Begin treatment according to assigned group code.†  
2. Every minute, assess the intensity of the participant’s pain via the NPRS. In 
addition, halfway through each interval of the treatment i.e. “baseline”, 
“exercise”, “occlusion”, and “recovery”, record the participant’s blood pressure 
and heart rate from the monitor.  
3. Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and slowly 
adjust the intensity to just above sensory threshold (no pain or muscle 
contraction) by asking the participant when he/she begins to feel a strong, but 
comfortable tingling sensation. 
4. Begin 1 min metronome and instruct participant to verbalize his or her pain level 
every min. 
5. Begin 1.5 min metronome and collect BP & HR data every 1.5 min. 
6. Begin recording baseline blood flow for 3 minutes at resting heart rate. 
7. Place the hand dynamometer in the participant’s left hand. Instruct the participant 
to perform a static handgrip exercise for 3 minutes at 25% MVC.  
8. Five seconds before exercise completion, inflate the sphygmomanometer cuff to 
180 mmHg.! 
9. Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording blood 
flow.   
10. Deflate the cuff immediately and record for 3 minutes.  
11. Stop recording.   
12. Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at the 
end of each interval.   
13. Detach all equipment from the participant and wait at least 10 minutes before 
beginning the next treatment.   
 
* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects" 
Vieira, et. al. 
† Group codes: Placebo/PECO- (P-), Placebo/PECO+ (P+), TENS/PECO- (T-), TENS/PECO+ (T+), IFC/PECO- (I-), IFC/PECO+(I+) 
! Only if PECO+ group 
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Appendix G: Sample of Data Master 
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Appendix H: Numeric Pain Scale (NRS) and Faces Pain Scale 
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Appendix I: Modified Short-Form McGill Pain and Paresthesia Questionnaire  
 
 
  
103 
 
Appendix J: Prediction Expression for Changes in Vascular Resistance 
Prediction Expression: 
log10(VR+10) = Average change in VR + Phase + Treatment + Phase*Treatment + Ischemia 
+Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject 
Expanded Prediction Expression: 
 
log10(VR+10) = 
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Appendix K: Prediction Expression for ∆MPQ and ∆Faces Pain 
∆MPQ Pain: 
 
∆Faces Pain: 
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Appendix L: Prediction Expression for Changes in Vascular Resistance and Pain 
 
Prediction Expression: 
log10(VR+10) = ∆𝑉𝑅̅̅ ̅̅ ̅̅  + Phase + Ischemia + Treatment + MPQ + Phase*MPQ + 
Ischemia*MPQ + Treatment*MPQ + Subject 
 
Expanded Prediction Expression: 
log10(VR+10) = 
 
 
  
106 
 
Appendix M: Mean Changes in Hemodynamic Factors and Pain for Treatment 
Type by Ischemia and Phase 
 
 
 
 
A 
B 
107 
 
 
 
Figure 3.9: Mean Changes in Non-Significant Hemodynamic Factors for Treatment 
Types by Ischemia and Phase. A. Change in contralateral blood flow. B. Change in 
local blood flow. C. Change in mean arterial pressure (MAP). D. Change in Skin 
Temperature. E. Change in heart rate. Values are shown as means ± SE. 
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Figure 3.10: Mean Changes in Pain for Treatment Type by Ischemia and Phase. A. 
Change in Faces pain. B. Change in NRS Pain. C. Change in MPQ Pain. Values are 
shown as means ± SE. 
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Appendix N: Hemodynamic and Pain Trends during Exercise, Occlusion, and 
Recovery 
 
A 
B 
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Figure 3.11: Trends in Hemodynamic Factors during Exercise, Occlusion, and 
Recovery Phases. A. Local blood flow. B. Contralateral blood flow. C. Skin 
temperature. D. Heart rate (HR). E. Mean blood pressure (MBP). F. Vascular resistance 
(VR). Absolute changes in hemodynamic factors during the static handgrip exercise, after 
exercise with (PECO+, gray lines) and without (PECO-, black lines) circulatory 
occlusion, and during recovery in healthy young individuals with IFC (continuous lines), 
TENS (dotted lines), and placebo (dashed lines). Values are shown as means ± SE. 
E 
F 
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Figure 3.12: Change in Pain during Exercise, Occlusion, and Recovery Phases. A. 
NRS pain. B. Faces pain. C. MPQ pain. Absolute changes in pain during the static 
handgrip exercise, after exercise with (PECO+, gray lines) and without (PECO-, black 
lines) circulatory occlusion, and during recovery in healthy young individuals with IFC 
(continuous lines), TENS (dotted lines), and placebo (dashed lines). Values are shown as 
means ± SE. 
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Appendix O: Effects of Phase, Treatment Type, and Ischemia on ∆𝑽𝑹̅̅ ̅̅  and Pain 
Different levels of each dependent variable, i.e. the O, E, and R levels of the 
phase variable, have a different effect on ∆𝑉𝑅̅̅ ̅̅  and ∆pain. These effects are denoted by 
the fixed effect coefficient α.  
 
Table 3.3: Effects of Phase, Treatment Type, and Ischemia on ∆𝑉𝑅̅̅ ̅̅ . The average ∆𝑉𝑅̅̅ ̅̅  
predicted by the dataset is offset by a value α for different phases, treatment types, and 
ischemic conditions. Using Tukey-Kramer’s for post hoc comparisons, levels that do not 
share a letter have different effects on ∆𝑉𝑅̅̅ ̅̅  (p ≤ 0.01). 
Factor p Value Level Tukey 
Fixed Effect 
Coeff 
Effect on ∆𝑉𝑅̅̅ ̅̅ , 
[µmHg/PU] 
Phase <0.0001 O A    𝛼𝑂 +93.4 
 E   B  𝛼𝐸 -41.3 
 R   B  𝛼𝑅 -52.0 
Treatment Type 0.0005 I A    𝛼𝐼 +11.2 
 T A B  𝛼𝑇 +2.00 
 P   B  𝛼𝑃 -13.2 
Ischemia <0.0001 PECO+ A   𝛼𝑃𝐸𝐶𝑂+ +37.0 
 PECO-  B  𝛼𝑃𝐸𝐶𝑂− -37.0 
Phase*Ischemia <0.0001 O,+ A     𝛼𝑂𝛼𝑃𝐸𝐶𝑂+ +91.9 
 O,-   B   𝛼𝑂𝛼𝑃𝐸𝐶𝑂− -91.1 
 R,-   B   𝛼𝑅𝛼𝑃𝐸𝐶𝑂− +53.1 
 E,-   B C 𝛼𝐸𝛼𝑃𝐸𝐶𝑂− +38.7 
 E,+   B C 𝛼𝐸𝛼𝑃𝐸𝐶𝑂+ -38.7 
 R,+     C 𝛼𝑅𝛼𝑃𝐸𝐶𝑂+ -53.1 
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Table 3.4: Effects of Phase and Ischemia on Change in Pain. The average pain 
predicted by the dataset is offset by a value α for different phases and ischemic 
conditions, while treatment type has no significant effect. Using Tukey-Kramer’s for post 
hoc comparisons, levels that do not share a letter have different effects on change in pain 
(p ≤ 0.01).  
Factor p value Level Tukey Effect Coeff 
Effect, 𝛼 
[∆MPQ Pain] 
Effect, 𝛼 
[∆Faces Pain]  
Phase <.0001 O A   𝛼𝑂 +1.02 +75.8 
  E  B  𝛼𝐸 +0.534 +0.0813 
  R   C 𝛼𝑅 - -75.9 
Ischemia <.0001 + A   𝛼+ +0.606 +77.9 
  -  B  𝛼− -0.606 -77.9 
Ischemia*
Phase 
<.0001 O,+ A   𝛼𝑂𝛼+ +1.12 +121 
 E,+  B  𝛼𝐸𝛼+ +0.513 +59.5 
 E,-  B  𝛼𝐸𝛼− -0.513 -59.5 
 R,-  B C 𝛼𝑅𝛼− - +61.4 
 R,+  B C 𝛼𝑅𝛼+ - -61.4 
 O,-   C 𝛼𝑂𝛼− -1.12 -121 
 
 
Table 3.5: Effects of Pain on ∆𝑉𝑅̅̅ ̅̅ . The relationship between ∆𝑉𝑅̅̅ ̅̅  and MPQ pain is 
dependent on the interactions between phase and treatment type effects, α, and a slope 
coefficient, β. For every 1 µmHg/PU increase in ∆𝑉𝑅̅̅ ̅̅ , different phases or ischemic 
conditions have a different effect on the slope, β, describing the relationship between 
∆𝑉𝑅̅̅ ̅̅  and ∆MPQ pain. Using Tukey-Kramer’s for post hoc comparisons, levels that do 
not share a letter have different effects on ∆𝑉𝑅̅̅ ̅̅  (p ≤ 0.05).  
Factor p value Level Tukey Fixed Effect  
Slope Effect, β 
[µmHg/PU∙MPQ] 
∆MPQ Pain*Ischemia 0.0121 PECO+ A  𝛽1𝛼𝑃𝐸𝐶𝑂+ -2.81 
  PECO-  B 𝛽1𝛼𝑃𝐸𝐶𝑂− +23.3 
∆MPQ Pain*Phase <.0001 O A  𝛽1𝛼𝑂 +23.6 
  E  B 𝛽1𝛼𝐸 -1.42 
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Appendix P: Variability in Pain associated with Paresthesia  
 
 
 
Figure 3.13: Paresthesia and Pain Variability between Subjects. A. Significant 
between-subject variability occurred in self-reported changes in MPQ pain when 
paresthesia descriptors were included in the questionnaire. B. Tukey post-hoc 
comparisons show that participants felt significant paresthesia with TENS treatment as 
compared to placebo (T-P). Values shown as means ± SE. 
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